腎と透析 Vol.86 2019年増刊号 全身性疾患と腎update

出版社: 東京医学社
発行日: 2019-06-20
分野: 臨床医学:内科  >  雑誌
ISSN: 03852156
雑誌名:
特集: 全身性疾患と腎update
電子書籍版: 2019-06-20
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

9,900 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

9,900 円(税込)

目次

  • 特集 全身性疾患と腎update

    第1章 膠原病,血管炎,自己免疫疾患
     1.全身性エリテマトーデス
     2.混合性結合組織病
     3.全身性強皮症
     4.関節リウマチ
     5.シェーグレン症候群
     6.抗リン脂質抗体症候群
     7.高安動脈炎
     8.結節性多発動脈炎
     9.顕微鏡的多発血管炎
     10.多発血管炎性肉芽腫症
     11.好酸球性多発血管炎性肉芽腫症
     12.抗糸球体基底膜抗体病
     13.IgA血管炎
     14.クリオグロブリン血症性血管炎
     15.サルコイドーシス
     16.IgG4関連疾患
     17.尿細管間質性腎炎ぶどう膜炎(TINU)症候群

    第2章 代謝性疾患
     1.糖尿病性腎症
     2.高尿酸血症,痛風
     3.脂質代謝障害
     4.Fabry病
     5.肥満症
     6.ミトコンドリア病
     7.アミノ酸代謝異常―腎不全や高血圧とアミノ酸
     8.糖原病
     9.核酸代謝異常症―尿路結石を合併する疾患について
     10.オキサローシス
     11.シスチノーシス(シスチン症,シスチン蓄積症)

    第3章 血管疾患
     1.動脈硬化
     2.コレステロール塞栓症
     3.血栓症

    第4章 血圧異常
     1.高血圧
     2.高血圧緊急症(悪性高血圧)
     3.低血圧(ショック)

    第5章 血液疾患
     1.血栓性微小血管症
     2.溶血性尿毒症症候群
     3.非典型溶血性尿毒症症候群
     4.POEMS症候群(Crow-Fukase症候群)
     5.Castleman病,TAFRO症候群
     6.多発性骨髄腫
     7.アミロイドーシス
     8.M蛋白血症
     9.白血病
     10.発作性夜間ヘモグロビン尿症
     11.悪性リンパ腫
     12.播種性血管内凝固症候群

    第6章 感染症
     1.溶連菌感染症
     2.メチシリン耐性黄色ブドウ球菌感染症
     3.エルシニア感染症
     4.敗血症
     5.結核症
     6.梅毒
     7.寄生虫感染症
     8.HIV感染症
     9.レプトスピラ症(Weil病)
     10.マラリアと腎障害
     11.腎移植におけるウイルス感染症
     12.その他の細菌感染症

    第7章 遺伝性疾患
     1.Alport症候群
     2.ネイルパテラ症候群
     3.ネフロン癆
     4.補体制御異常
     5.多発性囊胞腎

    第8章 電解質異常
     1.高カルシウム血症
     2.低カリウム血症

    第9章 その他
     1.熱傷と急性腎不全
     2.横紋筋融解症
     3.熱中症
     4.妊娠高血圧症候群

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 膠原病, 血管炎, 自己免疫疾患

P.13 掲載の参考文献
1) 三森明夫 : 膠原病診療ノート 第3版, 日本医事新報社, 東京, 2013
2) McKinney EF, Lee JC, Jayne DR, et al : T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523 : 612-616, 2015
4) Gatto M, Zen M, Iaccarino L, et al : New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 15 : 30-48, 2019
5) Gladman DD, Iban-ez D, Urowitz MB : Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29 : 288-291, 2002
P.16 掲載の参考文献
1) 廣村桂樹, 池内秀和, 加家壁健, 他 : 日本腎生検レジストリー (J-RBR) からみた, わが国のループス腎炎の実態. 腎臓内科・泌尿器科 9 : 297-303, 2019
2) Weening JJ, D' Agati VD, Schwartz MM, et al : The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15 : 241-250, 2004
3) Bajema IM, Wilhelmus S, Alpers CE, et al : Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis : clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 93 : 789-796, 2018
4) Hahn BH, McMahon MA, Wilkinson A, et al : American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64 : 797-808, 2012
5) Kidney Disease : Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group : KDIGO Clinical Practice Guideline for Glomerulonephritis. Chapter 12 : Lupus nephritis. Kidney Int Suppl 2 : 221-232, 2012
6) Bertsias GK, Tektonidou M, Amoura Z, et al : Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71 : 1771-1782, 2012
7) Rovin BH, Solomons N, Pendergraft WF, 3rd, et al : A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95 : 219-231, 2019
8) Tektonidou MG, Dasgupta A, Ward MM : Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015 : a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68 : 1432-1441, 2016
P.20 掲載の参考文献
2) 近藤啓文 : 混合性結合組織病の病態, 治療と関連する遺伝的因子, 自己抗体の研究. 厚生労働科学研究費補助金難治性疾患克服研究事業混合性結合組織病に関する研究班, 平成16年度報告書, pp1-6, 2005
3) 吉田俊治, 深谷修作, 京谷晋吾, 他 : 混合性結合組織病 (MCTD) の肺動脈性肺高血圧症 (PAH) 診断の手引き改訂について. 厚生労働省難治性疾患克服研究事業 混合性結合組織病の病態解明と治療法の確立に関する研究班, 平成22年度報告書, pp7-13, 2011
4) 三森経世 : MCTDの重症度. 三森経世 (編) : 混合性結合組織病の診療ガイドライン (改訂第3版), 厚生労働科学研究費補助金難治性疾患克服研究事業混合性結合組織病の病態解明と治療法の確立に関する研究班, p8, 2011
5) 吉田俊治 : 肺高血圧症. 三森経世 (編) : 混合性結合組織病の診療ガイドライン (改訂第3版), 厚生労働科学研究費補助金難治性疾患克服研究事業混合性結合組織病の病態解明と治療法の確立に関する研究班, pp27-32, 2011
P.23 掲載の参考文献
1) Benjamin C, Carlo Alberto S, Rosaria T, et al : Mixed connective tissue disease : state of the art on clinical practice guidelines. RMD Open 4 (Suppl 1) : e000783, 2018
2) Kitridou RC, Akmal M, Turkel SB, et al : Renal involvement in mixed connective tissue disease : a longitudinal clinicopathologic study. Semin Arthritis Rheum 16 : 135-145, 1986
3) Dima A, Jurcut C, Baicus C : The impact of anti-U1-RNP positivity : systemic lupus erythematosus versus mixed connective tissue disease. Rheumatol Int 38 : 1169-1178, 2018
4) Ichikawa K, Konta T, Sato H, et al : The clinical and pathological characteristics of nephropathies in connective tissue diseases in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 21 : 1024-1029, 2017
5) Reiseter S, Gunnarsson R, Corander J, et al : Disease evolution in mixed connective tissue disease : results from a long-term nationwide prospective cohort study. Arthritis Res Ther 19 : 284, 2017
P.27 掲載の参考文献
1) Woodworth TG, Suliman YA, Li W, et al : Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 12 : 678-691, 2016
2) 桑名正隆 : 全身性強皮症. 最新醫學別冊診断と治療のABC 139 : 134-142, 2018
3) van den Hoogen F, Khanna D, Fransen J, et al : 2013 classification criteria for systemic sclerosis : an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 : 2737-2747, 2013
4) Volkmann ER, Tashkin DP, Sim M, et al : Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis 78 : 122-130, 2019
P.30 掲載の参考文献
1) Steen VD, Medsger TA Jr : Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41 : 1613-1619, 1998
2) Denton CP, Lapadula G, Mouthon L, et al : Renal complications and scleroderma renal crisis. Rheumatology (Oxford) 48 (Suppl 3) : iii32-iii35, 2009
3) Penn H, Howie AJ, Kingdon EJ, et al : Scleroderma renal crisis : patient characteristics and long-term outcomes. QJM 100 : 485-494, 2007
4) Steen VD, Costantino JP, Shapiro AP, et al : Outcome of renal crisis in systemic sclerosis : relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113 : 352-357, 1990
5) Pham PT, Pham PC, Danovitch GM, et al : Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft : case report and review of the literature. Am J Transplant 5 : 2565-2569, 2005
P.35 掲載の参考文献
1) Smolen JS, Aletaha D, McInnes IB : Rheumatoid arthritis. Lancet 388 : 2023-2038, 2016
2) Smolen JS, Breedveld FC, Burmester GR, et al : Treating rheumatoid arthritis to target : 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 : 3-15, 2016
3) Tanaka Y : Next stage of RA treatment : is TNF-inhibitor-free remission will be a possible treatment goal? Ann Rheum Dis 72 : ii124-ii127, 2013
4) Tanaka Y : Rheumatoid arthritis : DMARD de-escalation-let the patient guide you. Nat Rev Rheumatol 13 : 637-638, 2017
5) Tanaka Y : The JAK inhibitors : do they bring a paradigm shift for the management of rheumatic diseases? Rheumatology 58 (Suppl 1) : i1-i3, 2019
P.38 掲載の参考文献
1) 中野正明 : 関節リウマチの合併症 腎障害. 日本臨牀増刊 5 : 523-526, 2010
2) Nakano M, Ueno M, Nishi S, et al : Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 50 : 154-160, 1998
3) 中野正明, 長谷川尚, 黒田毅, 他 : 続発性アミロイドーシス. リウマチ科 31 : 264-271, 2004
4) Kuroda T, Tanabe N, Nakano M, et al : Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis. J Rheumatol 39 : 1348-1354, 2012
5) Nozawa Y, Sato H, Nakano M, et al : Utility of estimated glomerular filtration rate using cystatin C and its interpretation in patients with rheumatoid arthritis under glucocorticoid therapy. Clin Chim Acta 487 : 299-305, 2018
P.46 掲載の参考文献
1) 住田孝之 (監) : シェーグレン症候群診療ガイドライン 2017年版, 診断と治療社, 東京, 2017
2) Sumida T, Azuma N, Moriyama M, et al : Clinical practice guideline for Sjogren's syndrome 2017. Mod Rheumatol 28 : 383-408, 2018
P.49 掲載の参考文献
1) Fujieda Y, Atsumi T, Amengual O, et al : Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus 21 : 1506-1514, 2012
2) Otomo K, Atsumi T, Amengual O, et al : Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 64 : 504-512, 2012
3) 渥美達也 : 抗リン脂質抗体症候群. 腎と透析 84 : 572-578, 2018
5) Tektonidou MG : Renal involvement in the antiphospholipid syndrome (APS) -APS nephropathy. Clin Rev Allergy Immunol 36 : 131-140, 2009
P.53 掲載の参考文献
1) Gracia-Tello B, Isenberg D : Kidney disease in primary anti-phosphlipid antibody syndrome. Rheumatology 56 : 1069-1080, 2017
2) de Azevedo FVA, Maia DG, de Carvalho JF, et al : Renal involvement in antiphospholipid syndrome. Rheumatol Int 38 : 1777-1789, 2018
3) Turrent-Carriles A, Herrera-Felix JP, Amigo MC : Renal involvement in antiphospholipid syndrome. Front Immunol 9 : 1008, 2018
P.57 掲載の参考文献
1) Isobe M, Arimura Y, Harigai M, et al : Guidelines for management of vasculitis syndrome (JCS 2017) [http://www.j-circ.or.jp/guideline/pdf/JCS2017_isobe_h.pdf], 2018
2) Matsuura K, Ogino H, Kobayashi J, et al : Surgical treatment of aortic regurgitation due to Takayasu arteritis : long-term morbidity and mortality. Circulation 112 : 3707-3712, 2005
3) Perera AH, Youngstein T, Gibbs RG, et al : Optimizing the outcome of vascular intervention for Takayasu arteritis. Br J Surg 101 : 43-50, 2014
4) Kim YW, Kim DI, Park YJ, et al : Surgical bypass vs endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis. J Vasc Surg 55 : 693-700, 2012
5) Park HS, Do YS, Park KB, et al : Long term results of endovascular treatment in renal arterial stenosis from Takayasu arteritis : angioplasty versus stent placement. Eur J Radiol 82 : 1913-1918, 2013
P.61 掲載の参考文献
1) 日本循環器学会, 他 (編) : 血管炎症候群の診療ガイドライン (2017年改訂版), 2017
2) Cui X, Qin F, Song L, et al : Novel biomarkers for the precisive diagnosis and activity classification of Takayasu arteritis. Circ Genom Precis Med 12 : e002080, 2019
3) Oguro E, Ohsima S, Kikuchi-Taura A, et al : Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) as a novel imaging modality for disease activity assessment in Takayasu's arteritis : a case report. Intern Med, 2019 Jan 10 [Epub ahead of print]
4) Nakaoka Y, Isobe M, Takei S, et al : Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis : results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77 : 348-354, 2018
5) Tanacan A, Unal C, Yucesoy HM, et al : Management and evaluation of pregnant women with Takayasu arteritis. Arch Gynecol Obstet 299 : 79-88, 2019
P.65 掲載の参考文献
1) Marc Hochberg, et al : Rheumatology, 7th Edn, pp301-302, 1358-1363, Elsevier, Amsterdam, 2018
2) 公益財団法人日本リウマチ財団教育研修委員会 (編), 一般社団法人日本リウマチ学会生涯教育委員会 (編) : リウマチ病学テキスト改訂第2版, pp253-256, 診断と治療社, 東京, 2016
3) 日本循環器学会, 厚生労働省難治性疾患政策研究事業難治性血管炎に関する調査研究班ほか : 血管炎症候群の診療ガイドライン (2017年改訂版), pp50-53, 東京 (http://www.j-circ.or.jp/guideline/pdf/JCS2017_isobe_h.pdf, 2018年11月12日アクセス)
4) 難病情報センター (http://www.nanbyou.or.jp/entry/244, 2018年11月12日アクセス)
5) Guillevin L, Lhote F, Gayraud M, et al : Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75 : 17-28, 1996
P.68 掲載の参考文献
1) Davies DJ, Moran JE, Niall JF, et al : Segmental necrotising glomerulonephritis with antineutrophil antibody : possible arbovirus aetiology? Br Med J (Clin Res Ed) 285 : 606, 1982
2) van der Woude FJ, Rasmussen N, Lobatto S, et al : Autoantibodies against neutrophils and monocytes : tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1 (8426) : 425-429, 1985
3) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013
4) Navon Elkan P, Pierce SB, Segel R, et al : Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370 : 921-931, 2014
5) Hernandez-Rodriguez J, Alba MA, Prieto-Gonzalez S, et al : Diagnosis and classification of polyarteritis nodosa. J Autoimmun 48-49 : 84-89, 2014
6) Arkin A : A clinical and pathological study of periarteritis nodosa : a report of five cases, one histologically healed. Am J Pathol 6 : 401-426, 1930
7) Ozen S : The changing face of polyarteritis nodosa and necrotizing vasculitis. Nat Rev Rheumatol 13 : 381-386, 2017
8) De Virgilio A, Greco A, Magliulo G, et al : Polyarteritis nodosa : a contemporary overview. Autoimmun Rev 15 : 564-570, 2016
P.72 掲載の参考文献
1) 有村義宏, 丸山彰一, 本間栄 (編) : ANCA関連血管炎診療ガイドライン 2017, pp58-60, 診断と治療社, 東京, 2017
2) 難治性血管炎に関する調査研究斑, 進行性腎障害に関する調査研究斑 : ANCA関連血管炎の診療ガイドライン (2017年改訂版), 2017
5) Pagnoux C, Mahr A, Hamidou MA, et al : Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359 : 2790-2803, 2008
P.78 掲載の参考文献
1) Sada KE, Yamamura M, Harigai M, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014
2) 有村義宏, 他 : ANCA関連血管炎診療ガイドライン 2017, p58-60, 診断と治療社, 東京, 2017
3) 丸山彰一 (監修) : エビデンスに基づく急性進行性腎炎症候群 (RPGN) 診療ガイドライン 2017, 東京医学社, 東京, 2017
4) 新田孝作, 他 : わが国の慢性透析療法の現況 (2017年12月31日現在). 透析会誌 51 : 699-766, 2018
5) Jennette JC, Nachman PH : ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 12 : 1680-1691, 2017
6) Chen SF, Wang H, Huang YM, et al : Clinicopathologic characterisitics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin J Am Soc Nephrol 10 : 750-758, 2015
7) Trejo MW, van Daalen E, Wolterbeek R, et al : Differences in renal histopathology between PR3-ANCA-associated vasculitis and MPO-ANCA-associated vasculitis. Rheumatology 58 (Suppl 2) : ii50-ii51, 2019 (abstract)
8) Joh K, Muso E, Shigematsu H, et al : Renal pathology of ANCA-related vasculitis : proposal for standardization of pathological diagnosis in Japan. Clin Exp Nephrol 12 : 277-291, 2008
10) Chen YX, Xu J, Pan XX, et al : Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis : a study of 186 patients and metaanalysis. J Rheumatol 44 : 304-313, 2017
11) Neumann I, Kain R, Regele H, et al : Histological and clinical predictors of early and late renal outcome in ANCA-associated vasculitis. Nephrol Dial Transplant 20 : 96-104, 2005
12) Chen Y, Bao H, Liu Z, et al : Risk factors for renal survival in Chinese patients with myeloperoxidase-ANCA-associated GN. Clin J Am Soc Nephrol 12 : 417-425, 2017
13) Menez S, Hruskova Z, Scott J, et al : Predictors of renal outcomes in sclerotic class anti-neutrophil cytoplasmic antibody glomerulonephritis. Am J Nephrol 48 : 465-471, 2018
14) Berden AE, Jones RB, Erasmus DD, et al : Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-asscociated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 23 : 313-321, 2012
15) Brix SR, Noriega M, Tennstedt P, et al : Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94 : 1177-1188, 2018
16) Yamagata K, Usui J, Nagata M, et al : Histopathological classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a nationwide Japanese prospective 2-year follow-up cohort study. Clin Exp Nephrol 23 : 387-394, 2019
17) Ntatsaki E, Carruthers D, Chakravarty K, et al : BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53 : 2306-2309, 2014
20) Jones RB, Furuta S, Tervaert JW, et al : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis : 2-year results of a randomised trial. Ann Rheum Dis 74 : 1178-1182, 2015
21) Geetha D, Specks U, Stone JH, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculi tis with renal involvement. J Am Soc Nephrol 26 : 976-985, 2015
22) McAdoo SP, Medjeral-Thomas N, Gopaluni S, et al : Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 34 : 63-73, 2019
23) Rovin BH, Caster DJ, Cattran DC, et al : Management and treatment of glomerular diseases (part 2) : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95 : 281-295, 2019
24) Jayne DR, Gaskin G, Rasmussen N, et al : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18 : 2180-2188, 2007
25) Walsh M, Merkel P, Peh CA, et al : The effect of plasma exchange on end-stage renal disease and death in patients with severe ANCA-associated vasculitis (PEXIVAS). Nephrol Dial Transplant 33 : i636, 2018
26) Moura MC, Mira MI, Massat AE, et al : Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe renal disease. Rheumatology 58 (Supple 2) : 128-129, 2019
28) Terrier B, Pagnoux C, Perrodeau E, et al : Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77 : 1150-1156, 2018
29) Jones RB, Hiemstra TF, Ballarin J, et al : Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis : a randomised, non-inferiority trial. Ann Rheum Dis 78 : 399-405, 2019
30) Charles P, Terrier B, Perrodeau E, et al : Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission : results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77 : 1143-1149, 2018
31) Xiao H, Dairaghi DJ, Powers JP, et al : C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25 : 225-231, 2014
32) Jayne DRW, Bruchfeld AN, Harper L, et al : Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 28 : 2756-2767, 2017
33) Kemna MJ, Damoiseaux J, Austen J, et al : ANCA as a predictor of relapse : useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 26 : 537-542, 2015
34) Rhee RL, Davis JC, Ding L, et al : The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis. Clin J Am Soc Nephrol 13 : 251-257, 2018
P.83 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013
2) Fujimoto S, Watts RA, Kobayashi S, et al : Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology (Oxford) 50 : 1916-1920, 2011
3) Sada KE, Yamamura M, Harigai M, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014
4) Harabuchi Y, Kishibe K, Tateyama K, et al : Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (OMAAV) : a retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol 27 : 87-94, 2017
5) 吉田雅治, 他 ; 厚生省特定疾患免疫疾患調査研究班 : 難治性血管炎分科会, 平成10年度報告書, pp239-246, 1999
6) Craven A, Robson J, Ponte C, et al : ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol 17 : 619-621, 2013
8) Jones RB, Tervart JW, Hauser T, et al : Rituximab versus cyclophosphamide in ANCA-associated renal vascultis. N Engl J Med 363 : 211-220, 2010
P.91 掲載の参考文献
1) Jennette JC, Nachman PH : ANCA glomerulonephritis and vasculitis. Clin J Am Soc Nephrol 12 : 1680-1691, 2017
2) 土屋尚之 : 多発血管性肉芽腫症 (1) 疫学・遺伝疫学. 日本臨牀76 増 (血管炎 (第2版)) : 238-244, 2018
3) Ono N, Niiro H, Ueda A, et al : Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis : a retrospective multi-center study in Japan. Rheumatol Int 35 : 555-559, 2015
4) Lamprecht P, Kerstein A, Klapa S, et al : Pathogenetic and clinical aspects of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Front Immunol 9 : 680, 2018
5) Greco A, Marinelli C, Fusconi M, et al : Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol 29 : 151-159, 2016
6) Masiak A, Zdrojewski Z, Peksa R, et al : The usefulness of histopathological examinations of non-renal biopsies in the diagnosis of granulomatosis with polyangiitis. Reumatologia 55 : 230-236, 2017
7) 松原修, 山本宗平, 小林隆之, 他 : Wegener肉芽腫症の病理像-呼吸器を中心として-. 日胸 67 : 228-238, 2008
8) Colvin RB, Chang A (eds) : Diagnostic Pathology : Kidney Disease, 2nd Ed, pp478-487, Elsevier, 2015
9) Chang SY, Keogh KA, Lewis JE, et al : IgG4-positive plasma cells in granulomatosis with polyangiitis (Wegener's) : a clinicopathologic and immunohistochemical study on 43 granulomatosis with polyangiitis and 20 control cases. Hum Pathol 44 : 2432-2437, 2013
10) Danlos FX, Rossi GM, Blockmans D, et al : Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease : a new overlap syndrome. Autoimmun Rev 16 : 1036-1043, 2017
P.93 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013
2) Sada KE, Amano K, Uehara R, et al : A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol 24 : 640-644, 2014
4) 長澤俊彦, 吉田雅治 : アレルギー性肉芽腫性血管炎の本邦症例の臨床像と臨床診断基準の提唱. 日内会誌 78 : 352-356, 1989
5) Greco A, Rizzo MI, de Virgilio A, et al : Churg-Strauss syndrome. Autoimmun Rev 14 : 341-348, 2015
6) Wechsler ME, Akuthota P, Jayne D, et al : Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376 : 1921-1932, 2017
P.97 掲載の参考文献
1) Jennette JC, Falk RJ, Watts RA, et al : 2012 Revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 65 : 1-11, 2013
2) Sada KE, Yamamura M, Makino H, et al : Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 16 : R101, 2014
3) Durel CA, Berthiller J, Hot A, et al : Long-term follow up of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res 68 : 374-387, 2016
4) Groh M, Pagnoux C, Guillevin L, et al : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EPGA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26 : 545-553, 2015
5) Chen Y, Ding Y, Hu W, et al : Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement : a retrospective study of 14 Chinese patients. BMC Nephrol 17 : 101, 2016
P.101 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013
2) Goodpasture症候群. 日本呼吸器学会 (編) : 新呼吸器専門医テキスト, pp489-490, 南江堂, 東京, 2015
3) Goodpasture EW : The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci 158 : 863-870, 1919
4) Stanton MC, Tange JD : Goodpasture's syndrome : pulmonary haemorrhage associated with glomerulonephritis. Australas Ann Med 7 : 132-144, 1958
5) 坂東政司 : 呼吸器 17. 肺胞出血. 久保惠嗣 (監修) : 今日の診療サポート, エルゼビア・ジャパン, 2015 (https://clinicalsup.jp/contentlist/1662.html)
6) Serisier DJ, Wong RC, Armstrong JG : Alveolar haemorrhage in anti-glomerular basement membrane disease without detectable antibodies by conventional assays. Thorax 61 : 636-639, 2006
7) Levy JB, Hammad T, Coulthart A, et al : Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 66 : 1535-1540, 2004
8) Bosch X, Mirapeix E, Font J, et al : Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol 36 : 107-113, 1991
9) Nakabayashi K, Fujioka Y, Nagasawa T, et al : Dual myeloperoxidase-antineutrophil cytoplasmic anti-body and antiglomerular basement membrane antibody-positive cases associated with prior pulmonary fibrosis : a report of four cases. Clin Exp Nephrol 15 : 226-234, 2011
10) 厚生労働科学研究費補助金難治性疾患等政策研究事業 難治性腎疾患に関する調査研究班 (編) : エビデンスに基づく急速進行性腎炎症候群 (RPGN) 診療ガイドライン, 東京医学社, 東京, 2017
11) Kidney disease : Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Chapter 14 : Anti-glomerular basement membrane antibody glomerulonephritis. Kidney Int Suppl 2 : 240-242, 2012
P.105 掲載の参考文献
1) Segelmark M, Hellmark T : Anti-glomerular basement membrane disease : an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant, 2018 Oct 29 [Epub ahead of print]
3) Ooi JD, Petersen J, Tan YH, et al : Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545 : 243-247, 2017
4) Usui T, Kai H, Noguchi K, et al : Effectiveness of plasmapheresis in a patient with anti-glomerular basement membrane antibody glomerulonephritis with advanced kidney dysfunction. Intern Med 56 : 2475-2479, 2017
5) van Daalen EE, Jennette JC, McAdoo SP, et al : Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol 13 : 63-72, 2018
P.108 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013
4) Mills JA, Michel BA, Bloch DA, et al : The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 33 : 1114-1121, 1990
5) 難病情報センター : 紫斑病性腎炎 (指定難病224) (http://www.nanbyou.or.jp/entry/4658)
P.112 掲載の参考文献
1) Chan H, Tang YL, Li Q, et al : Risk factors associated with renal involvement in childhood Henoch-Schonlein purpura : a meta-analysis. PLoS One 11 : e0167346, 2016
2) Ozen S, Pistorio A, Ruperto N, et al : EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II : Final classification criteria. Ann Rheum Dis 69 : 798-806, 2010
4) Heineke MH, Ballering AV, Jamin A, et al : New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schonlein purpura). Autoimmun Rev 16 : 1246-1253, 2017
5) Suzuki H, Yasutake J, Suzuki Y, et al : IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int 93 : 700-705, 2018
P.116 掲載の参考文献
1) De Vita S, Soldano F, Isola M, et al : Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis 70 : 1183-1190, 2011
2) 日本循環器学会, 他 : 血管炎症候群の診療ガイドライン (2017年改訂版), 2018
3) Terrier B, Cacoub P : Cryoglobulinemia vasculitis : an update. Curr Opin Rheumatol 25 : 10-18, 2013
4) Dammacco F, Lauletta G, Russi S, et al : Clinical practice : hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med 19 : 1-21, 2019
5) Muchtar E, Magen H, Gertz MA : How I treat cryoglobulinemia. Blood 129 : 289-298, 2017
P.121 掲載の参考文献
1) Rosa D, Saletti G, De Gregorio E, et al : Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 102 : 18544-18549, 2005
2) Colvin and Chang, Type I cryoglobulinemic glomerulonephritis. Diagnostic Pathology, Kidney Diseases, 2nd Edn, pp215, Elsevier, Philadelphia, 2016
3) Sethi S, Yachoui R, Murray DL, et al : Cryofibrinogen-associated glomerulonephritis. Am J Kidney Dis 69 : 302-308, 2017
4) Gupta V, El Ters M, Kashani K, et al : Crystalglobulin-induced nephropathy. J Am Soc Nephrol 26 : 525-529, 2015
P.124 掲載の参考文献
1) Negi M, Takemura T, Guzman J, et al : Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol 25 : 1284-1297, 2012
2) 藤本公則 : サルコイドーシスの胸部画像診断. 日サ会誌 33 : 31-34, 2013
P.127 掲載の参考文献
1) Baughman RP, Teirstein AS, Judson MA, et al : Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164 (10 Pt 1) : 1885-1889, 2001
2) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシス診療の手引き 2018, 2018
3) Loffler C, Loffler U, Tuleweit A, et al : Renal sarcoidosis : epidemiological and follow-up data in a cohort of 27 patients. Sarcoidosis Vasc Diffuse Lung Dis 31 : 306-315, 2015
4) Bergner R, Hoffmann M, Waldherr R, et al : Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 20 : 126-132, 2003
5) Longcope WT, Freiman DG : A study of sarcoidosis ; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. Medicine 31 : 1-132, 1952
6) Berliner AR, Haas M, Choi MJ : Sarcoidosis : the nephrologist's perspective. Am J Kidney Dis 48 : 856-870, 2006
7) Branson JH, Park JH : Sarcoidosishepatic involvement : presentation of a case with fatal liver involvement ; including autopsy findings and review of the evidence for sarcoid involvement of the liver as found in the literature. Ann Intern Med 40 : 111-145, 1954
8) Muther RS, McCarron DA, Bennett WM : Renal manifestations of sarcoidosis. Arch Intern Med 141 : 643-645, 1981
9) Mahevas M, Lescure FX, Boffa JJ, et al : Renal sarcoidosis : clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine 88 : 98-106, 2009
10) Rajakariar R, Sharples EJ, Raftery MJ, et al : Sarcoid tubulo-interstitial nephritis : long-term outcome and response to corticosteroid therapy. Kidney Int 70 : 165-169, 2006
11) Falk S, Kratzsch J, Paschke R, et al : Hypercalcemia as a result of sarcoidosis with normal serum concentrations of vitamin D. Med Sci Monit 13 : CS133-CS136, 2007
12) Hamada K, Nagai S, Tsutsumi T, et al : Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J 11 : 1015-1020, 1998
13) Rizzato G, Palmieri G, Agrati AM, et al : The organ-specific extrapulmonary presentation of sarcoidosis : a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis 21 : 119-126, 2004
14) Levi M, Peterson L, Berl T : Mechanism of concentrating defect in hypercalcemia. Role of polydipsia and prostaglandins. Kidney Int 23 : 489-497, 1983
15) Celada LJ, Hawkins C, Drake WP : The etiologic role of infectious antigens in sarcoidosis pathogenesis. Clin Chest Med 36 : 561-568, 2015
16) Yamada T, Eishi Y, Ikeda S, et al : In situ localization of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J Pathol 198 : 541-547, 2002
17) Eishi Y : Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int 2013 : 935289, 2013
18) Nakamura T, Furukawa A, Uchida K, et al : Autophagy induced by intracellular infection of Propionibacterium acnes. PLoS One 11 : e0156298, 2016
19) Beijer E, Veltkamp M, Meek B, et al : Etiology and immunopathogenesis of sarcoidosis : novel insights. Semin Respir Crit Care Med 38 : 404-416, 2017
P.132 掲載の参考文献
1) Umehara H, Okazaki K, Masaki Y, et al : A novel clinical entity, IgG4-related disease (IgG4RD) : general concept and details. Mod Rheumatol 22 : 1-14, 2012
2) Uchida K, Masamune A, Shimosegawa T, et al : Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol 2012 : 358371, 2012
4) Shiokawa M, Kodama Y, Sekiguchi K, et al : Laminin 511 is a target antigen in autoimmune pancreatitis. Sci Transl Med 10 : eaaq0997, 2018
5) Kamisawa T, Shimosegawa T, Okazaki K, et al : Standard steroid treatment for autoimmune pancreatitis. Gut 58 : 1504-1507, 2009
P.136 掲載の参考文献
1) 川野充弘, 佐伯敬子, 中島衡, 他 : IgG4関連腎臓病診療指針. 日腎会誌 53 : 1062-1073, 2011
2) Yamada K, Yamamoto M, Saeki T, et al : New clues to the nature of immunoglobulin G4-related disease : a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 19 : 262, 2017
3) Yoshita K, Kawano M, Mizushima I, et al : Light-microscopic characteristics of IgG4-related tubulointerstitial nephritis : distinction from non-IgG4-related tubulointerstitial nephritis. Nephrol Dial Transplant 27 : 2755-2761, 2012
4) Alexander MP, Larsen CP, Gibson IW, et al : Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int 83 : 455-462, 2013
5) Saeki T, Kawano M, Mizushima I, et al : The clinical course of patients with IgG4-related kidney disease. Kidney Int 84 : 826-833, 2013
P.140 掲載の参考文献
1) Dobrin RS, Vernier RL, Fish AL : Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome. Am J Med 59 : 325-333, 1975
2) Mandeville JT, Levinson RD, Holland GN : The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 46 : 195-208, 2001
3) Okafor LO, Hewins P, Murray PI, et al : Tubulointerstitial nephritis and uveitis (TINU) syndrome : a systematic review of its epidemiology, demographics and risk factors. Orphanet J Rare Dis 12 : 128, 2017
4) Jia Y, Su T, Gu Y, et al : HLA-DQA1, -DQB1, and- DRB1 Alleles associated with acute tubulointerstitial nephritis in a Chinese population : a single-center cohort study. J Immunol 201 : 423-431, 2018
P.143 掲載の参考文献
1) Okafor LO, Hewins P, Murray PI, et al : Tubulointerstitial nephritis and uveitis (TINU) syndrome : a systematic review of its epidemiology, demographics and risk factors. Orphanet J Rare Dis 12 : 128, 2017
2) Clive DM, Vanguri VK : The syndrome of tubulointerstitial nephritis with uveitis (TINU). Am J Kidney Dis 72 : 118-128, 2018
3) Li C, Su T, Chu R, et al : Tubulointerstitial nephritis with uveitis in Chinese adults. Clin J Am Soc Nephrol 9 : 21-28, 2014
4) Joyce E, Glasner P, Ranganathan S, et al : Tubulointerstitial nephritis : diagnosis, treatment, and monitoring. Pediatr Nephrol 32 : 577-587, 2017
5) Yanagihara T, Kitamura H, Aki K, et al : Serial renal biopsies in three girls with tubulointerstitial nephritis and uveitis syndrome. Pediatr Nephrol 24 : 1159-1164, 2009

第2章 代謝性疾患

P.149 掲載の参考文献
1) Babazono T, Nyumura I, Toya K, et al : Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients. Diabetes Care 32 : 1518-1520, 2009
2) Coresh J, Heerspink HJL, Sang Y, et al : Change in albuminuria and subsequent risk of end-stage kidney disease : an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol 7 : 115-127, 2019
3) de Zeeuw D, Remuzzi G, Parving HH, et al : Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy : lessons from RENAAL. Kidney Int 65 : 2309-2320, 2004
4) 日本糖尿病対策推進会議. 日医雑誌 141 : 325-334, 2012
5) Coca SG, Ismail-Beigi F, Haq N, et al : Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus : systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172 : 761-769, 2012
6) Ueki K, Sasako T, Okazaki Y, et al : Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3) : an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5 : 951-964, 2017
7) Perkovic V, Jardine MJ, Neal B, et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 2019 Apr 14 [Epub ahead of print]
10) Ismail-Beigi F, Craven TE, O'Connor PJ, et al : Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 81 : 586-594, 2012
11) Viberti G, Wheeldon NM, et al : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus : a blood pressure-independent effect. Circulation 106 : 672-678, 2002
12) Makino H, Haneda M, Babazono T, et al : Prevention of transition from incipient to over nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30 : 1577-1578, 2007
13) Mauer M, Zinman B, Gardiner R, et al : Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361 : 40-51, 2009
P.154 掲載の参考文献
1) 日本透析医学会 : わが国の慢性透析療法の現況 (2016年12月31日現在). 透析会誌 51 : 1-51, 2018
2) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, pp104-110, 東京医学社, 東京, 2018
3) 和田隆志, 湯澤由紀夫 (監修), 佐藤博, 他 (編) : 糖尿病性腎症と高血圧性腎症の病理診断への手引き, pp15~47, 東京医学社, 東京, 2014
4) 和田隆志, 湯澤由紀夫, 乳原善文, 他 (編) : 糖尿病性腎症病期分類に基づいた腎病理診断の手引き, pp12-17, 2017
5) Mann JFE, Orsted DD, Brown-Frandsen K, et al : Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 : 839-848, 2017
6) Neal B, Perkovic V, Mahaffey KW et al : Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 : 644-657, 2017
P.158 掲載の参考文献
1) 上野征夫 : リウマチ病診療ビジュアルテキスト 第2版, 医学書院, 東京, 2008
2) Hochberg MC, et al (eds) : Rheumatology, 7th Edn, Elsevier, 2019
3) Wyngaarden JB, Kelley WN : Gout and Hyperuricemia, Grune & Stratton, New York, 1976
4) Katz WA, Schubert M : The interaction of monosodium urate with connective tissue components. J Clin Invest 49 : 1783-1789, 1970
5) So A : Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 10 : 221, 2008
6) Gibson T : Clinical features of gout. In : Hochiberg MC, Silman AJ, Smolen JS, et al (eds) : Rheumatology, pp1919-1928, Mosby, Edinburgh, 2003
7) Taylor WJ, Shewchuk R, Saag KG, et al : Toward a valid definition of gout flare : results of consensus exercises using Delphi methodology and cognitive mapping. Arthritis Rheum 61 : 535-543, 2009
8) Edwards NL : Gout : Presentation, natural history, and associated conditions. In : Wortmann RL, Schumacher, Jr HR, Becker MA, et al (eds) : Crystal-induced Arthropathies, pp61-79, Taylor & Francis, New York, 2006
9) Campion EW, Glynn RJ, DeLabry LO : Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82 : 421-426, 1987
10) Bardin T, Schiavon F, Punzi L : 1. Gout. In : Bijlsma JWJ, et al (eds) : Textbook on Rheumatic Diseases, pp344-372, BMJ, 2015
11) Kienhorst LB, Janssens HJ, Fransen J, et al : Arthritis of the first metatarsophalangeal joint is not always gout : a prospective cohort study in primary care patients. Joint Bone Spine 81 : 342-346, 2014
P.162 掲載の参考文献
1) Jalal DI, Chonchol M, Chen W, et al : Uric acid as a target of therapy in CKD. Am J Kidney Dis 61 : 134-146, 2013
2) Sanchez-Lozada LG, Tapia E, Santamaria J, et al : Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67 : 237-247, 2005
3) Kohagura K, Kochi M, Miyagi T, et al : An association between uric acid levels and renal arteriolopathy in chronic kidney disease : a biopsy-based study. Hypertens Res 36 : 43-49, 2013
4) Johnson RJ, Nakagawa T, Jalal D, et al : Uric acid and chronic kidney disease : which is chasing which? Nephrol Dial Transplant 28 : 2221-2228, 2013
5) Fogo A : Gouty nephropathy. Am J Kidney Dis 36 : E30, 2000
P.165 掲載の参考文献
1) Wanner C, Amann K, Shoji T : The heart and vascular system in dialysis. Lancet 388 : 276-284, 2016
2) Shoji T, Abe T, Matsuo H, et al : Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb 19 : 299-315, 2012
4) Kuwamura Y, Shoji T, Okute Y, et al : Altered serum n-6 polyunsaturated fatty acid profile and risks of mortality and cardiovascular events in a cohort of hemodialysis patients. J Ren Nutr 28 : 54-63, 2018
6) Sonoda M, Shoji T, Kimoto E, et al : Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus. J Atheroscler Thromb 21 : 346-354, 2014
8) Wanner C, Tonelli M, Kidney Disease : Improving Global Outcomes Lipid Guideline Development Work Group Members : KDIGO Clinical Practice Guideline for Lipid Management in CKD : summary of recommendation statements and clinical approach to the patient. Kidney Int 85 : 1303-1309, 2014
9) Shoji T, Inaba M, Fukagawa M, et al : Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis : the J-DAVID Randomized Clinical Trial. JAMA 320 : 2325-2334, 2018
P.169 掲載の参考文献
2) Fukunaga M, Nagahama K, Aoki M, et al : Membraonous nephropathy-like apolipoprotein E deposition disease with apolipoprotein E Toyonaka (Ser197Cys) and a homozygous apolipoprotein E2/2. Case Rep Nephrol Dial 8 : 45-55, 2018
3) Hirashima H, Komiya T, Toriu N, et al : A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka. Clin Nephrol Case Stud 6 : 45-51, 2018
4) Kato T, Ushiogi Y, Yokoyama H, et al : A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes. CEN Case Rep, 2019 Jan 30 [Epub ahead of print]
5) Georgiadou D, Stamatakis K, Efthimiadou EK, et al : Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy. J Lipid Res 54 : 164-176, 2013
6) Katsarou M, Stratikos E, Chroni A : Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy. J Lipid Res 59 : 2339-2348, 2018
7) Kodera H, Mizutani Y, Sugiyama S, et al : A case of lipoprotein glomerulopathy with apoE Chicago and apoE (Glu3Lys) treated with fenofibrate. Case Rep Nephrol Dial 7 : 112-120, 2017
8) Takasaki S, Matsunaga A, Joh K, et al : A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I. CEN Case Rep 7 : 127-131, 2018
9) Sasaki M, Yasuno T, Ito K, et al : Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys). CEN Case Rep 7 : 225-228, 2018
P.174 掲載の参考文献
1) ファブリー病診断治療ハンドブック編集委員会 (編) : ファブリー病診断治療ハンドブック改訂第3版, pp28-30, 2018
2) Politei JM, Bouhassira D, Germain DP, et al : Pain in Fabry disease : practical recommendations for diagnosis and treatment. CNS Neurosci Ther 22 : 568-576, 2016
3) Sakuraba H, Tsukimura T, Togawa T, et al : Fabry disease in a Japanese population-molecular and biochemical characteristics. Mol Genet Metab Rep 17 : 73-79, 2018
4) Hughes DA, Nicholls K, Shankar SP, et al : Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease : 18-month results from the randomised phase III ATTRACT study. J Med Genet 54 : 288-296, 2017
5) Schiffmann R, Hughes DA, Linthorst GE, et al : Screening, diagnosis, and management of patients with Fabry disease : conclusions from a 'Kidney Disease : Improving Global Outcomes' (KDIGO) Controversies Conference. Kidney Int 91 : 284-293, 2017
P.176 掲載の参考文献
1) Kobayashi M, Ohashi T, Sakuma M, et al : Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis 31 (Suppl 3) : 483-487, 2008
3) Eng CM, Fletcher J, Wilcox WR, et al : Fabry disease : baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30 : 184-192, 2007
4) Mignani R, Feriozzi S, Schaefer RM, et al : Dialysis and transplantation in Fabry disease : indications for enzyme replacement therapy. Clin J Am Soc Nephrol 5 : 379-385, 2010
5) Shah T, Gill J, Malhotra N, et al : Kidney transplant outcomes in patients with Fabry disease. Transplantation 87 : 280-285, 2009
P.180 掲載の参考文献
1) 肥満症診断基準検討委員会 : 肥満症診断基準 2011. 肥満研究 17 (臨時増刊), 2011
2) 日本肥満学会 (編) : 肥満症診療ガイドライン 2016, ライフサイエンス社, 東京, 2016
3) Hotamisligil GS, Shargill NS, Spiegelman BM : Adipose expression of tumor necrosis factor-alpha : direct role in obesity-linked insulin resistance. Science 259 : 87-91, 1993
4) 前田法一, 下村伊一郎 : 肥満症とアディポサイトカイン. 日内会誌 100 : 911-916, 2011
5) Muramoto A, Matsushita M, Kato A, et al : Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract 8 : e466-e475, 2014
6) Afshinnia F, Wilt TJ, Duval S, et al : Weight loss and proteinuria : systematic review of clinical trials and comparative cohorts. Nephrol Dial Transplant 25 : 1173-1183, 2010
P.186 掲載の参考文献
1) Kambham N, Markowitz GS, Valeri AM, et al : Obesity-related glomerulopathy : an emerging epidemic. Kidney Int 59 : 1498-1509, 2001
2) Praga M, Hernandez E, Morales E, et al : Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 16 : 1790-1798, 2001
3) Futatsugi K, Tokuyama H, Shibata S, et al : Obesity-induced kidney injury is attenuated by amelioration of aberrant PHD2 activation in proximal tubules. Sci Rep 6 : 36533, 2016
4) Hasegawa K, Wakino S, Simic P, et al : Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 19 : 1496-1504, 2013
P.191 掲載の参考文献
1) Murayama K, Shimura M, Liu Z, et al : Recent topics : the diagnosis, molecular genesis, and treatment of mitochondrial diseases. J Hum Genet 64 : 113-125, 2019
4) Distelmaier F, Haack TB, Wortmann SB, et al : Treatable mitochondrial diseases : cofactor metabolism and beyond. Brain 140 : e11, 2017
5) Imai-Okazaki A, Kishita Y, Kohda M, et al : Cardiomyopathy in children with mitochondrial disease : prognosis and genetic background. Int J Cardiol 279 : 115-121, 2019
6) 村山圭, 小坂仁, 米田誠 (日本ミトコンドリア学会編集) : ミトコンドリア病診療マニュアル 2017, 診断と治療社, 東京, 2016
P.195 掲載の参考文献
2) ミトコンドリア病診療マニュアル作成委員会 (村山圭, 小坂仁, 米田誠) (作成), 日本ミトコンドリア学会 (編集) : ミトコンドリア病診療マニュアル 2017, 診断と治療社, 東京, 2017
3) Suomalainen A, Elo JM, Pietilainen KH, et al : FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies : a diagnostic study. Lancet Neurol 10 : 806-818, 2011
5) Imasawa T, Tanaka M, Yamaguchi Y, et al : 7501 T > A mitochondrial DNA variant in a patient with glomerulosclerosis. Ren Fail 36 : 1461-1465, 2014
P.201 掲載の参考文献
1) 杤久保修, 安東敏彦 : アミノ酸と生活習慣病-最新アミノグラムで探る「いのち」の科学-, 女子栄養大学出版部, 東京, 2010
2) Laidlaw SA, Berg RL, Kopple JD, et al : Patterns of fasting plasma amino acid levels in chronic renal insufficiency : results from the feasibility phase of the Modification of Diet in Renal Disease Study. Am J Kidney Dis 23 : 504-513, 1994
3) Tochikubo O, Jinzu H, Nagao K, et al : Weight loss is associated with plasma free amino acid alterations in subjects with metabolic syndrome. Nutr Diabetes 6 : e197, 2016
4) 杤久保修 : アミノ酸と生活習慣病-健康長寿社会を目指して-. アミノ酸研究 9 : 5-13, 2015
5) Kopple JD, Levey AS, Greene T, et al : Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 52 : 778-791, 1997
P.206 掲載の参考文献
1) Chen YT, Coleman RA, Scheinman JI, et al : Renal disease in type I glycogen storage disease. N Engl J Med 318 : 7-11, 1988
2) Rake JP, Visser G, Labrune P, et al : Guidelines for management of glycogen storage disease type I-European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161 (Suppl 1) : S112-S119, 2002
3) Dambska M, Labrador EB, Kuo CL, et al : Prevention of complications in glycogen storage disease type Ia with optimization of metabolic control. Pediatr Diabetes 18 : 327-331, 2017
4) Kido J, Nakamura K, Matsumoto S, et al : Current status of hepatic glycogen storage disease in Japan : clinical manifestations, treatments and long-term outcomes. J Hum Genet 58 : 285-292, 2013
5) Okechuku GO, Shoemaker LR, Dambska M, et al : Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy. J Inherit Metab Dis 40 : 703-708, 2017
P.210 掲載の参考文献
1) 山田裕一 : HGPRT 欠損症 (Lesch-Nyhan症候群). 遠藤文夫 (総編集) : 先天代謝異常ハンドブック, pp282-283, 中山書店, 東京, 2013
2) 谷口敦夫 : アデニンホスホリボシルトランスフェラーゼ欠損症. 遠藤文夫 (総編集) : 先天代謝異常ハンドブック, pp284-285, 中山書店, 東京, 2013
3) 市田公美 : キサンチン尿症. 遠藤文夫 (総編集) : 先天代謝異常ハンドブック, pp289-290, 中山書店, 東京, 2013
4) 鷲見聡 : 遺伝性オロト酸尿症 (UMP合成酵素欠損症). 遠藤文夫 (総編集) : 先天代謝異常ハンドブック, pp296-297, 中山書店, 東京, 2013
P.215 掲載の参考文献
1) Cramer SD, Takayama T : Primary Hyperoxaluria, Chapter 33. In : Lifton R, et a (l ed) : Genetic Diseases of the Kidney, pp571-586, Elsevier, San Diego, 2009
2) Latta K, Brodehl J : Primary hyperoxaluria type I. Eur J Pediatr 149 : 518-522, 1990
3) Takayama T, Nagata M, Ichiyama A, et al : Primary hyperoxaluria type 1 in Japan. Am J Nephrol 25 : 297-302, 2005
4) Zhao F, Bergstralh EJ, Mehta RA, et al : Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11 : 119-126, 2016
5) Tang X, Bergstralh EJ, Mehta RA, et al : Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87 : 623-631, 2015
P.221 掲載の参考文献
1) 厚生労働省難治性疾患等政策研究事業 (難治性疾患政策研究事業) ライソゾーム病 (ファブリー病を含む) に関する調査研究班 : シスチノーシス診療ガイドライン 2018 (http://www.japan-lsd-mhlw.jp/pdf/Cystinnosis_Practice-guideline_2018.pdf)
2) Cherqui S, Courtoy PJ : The renal Fanconi syndrome in cystinosis : pathogenic insights and therapeutic perspectives. Nat Rev Nephrol 13 : 115-131, 2017
3) Higashi S, Matsunoshita N, Ito S, et al : Diagnostic challenge in a patient with nephropathic juvenile cystinosis : a case report. BMC Nephrol 18 : 300, 2017
4) 後藤芳光, 笠置俊希, 岡村匡史, 他 : ファンコーニ症候群, 腎機能低下から診断し, 幼少期からシステアミン投与を開始したシスチノーシス症例. 日腎誌 61 : 36-43, 2019
5) Elmonem MA, Veys K, Levtchenko E, et al : Allogeneic HSCT transfers wild-type cystinosin to nonhematological epithelial cells in cystinosis : first human report. Am J Transplant 18 : 2823-2828, 2018
6) Gahl WA, Balog JZ, Kleta R : Nephropathic cystinosis in adults : natural history and effects of oral cysteamine therapy. Ann Intern Med 147 : 242-250, 2007
7) Brodin-Sartorius A, Tete MJ, Niaudet P, et al : Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 81 : 179-189, 2012

第3章 血管疾患

P.230 掲載の参考文献
1) 日本動脈硬化学会 : 動脈硬化性疾患予防ガイドライン 2017年版, 2017
2) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 東京, 2018
3) McCullough PA : Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 13 : 591-600, 2004
4) Shoji T, Abe T, Matsuo H, et al : Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb 19 : 299-315, 2012
5) Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts : a collaborative meta-analysis. Lancet 375 : 2073-2081, 2010
6) Nishizawa Y, Shoji T, Maekawa K, et al : Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 41 (3 Suppl 1) : S76-S79, 2003
7) Shoji T, Maekawa K, Emoto M, et al : Arterial stiffness predicts cardiovascular death independent of arterial thickness in a cohort of hemodialysis patients. Atherosclerosis 210 : 145-149, 2010
9) Vaziri ND : Dyslipidemia of chronic renal failure : the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290 : F262-F272, 2006
10) Wanner C, Zimmermann J, Schwedler S, et al : Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 80 : 99-102, 2002
11) Stenvinkel P, Alvestrand A : Inflammation in end-stage renal disease : sources, consequences, and therapy. Semin Dial 15 : 329-337, 2002
12) Keane WF, Tomassini J, Neff DR : Lipid abnormalities in patients with chronic kidney disease : implications for the pathophysiology of atherosclerosis. J Atheroscler Thromb 20 : 123-133, 2013
13) Hirano T, Furukawa S, Kurokawa M, et al : Intracellular apoprotein B degradation is suppressed by decreased albumin concentration in Hep G2 cells. Kidney Int 47 : 421-431, 1995
14) Ikewaki K, Schaefer JR, Frischmann ME, et al : Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 25 : 2615-2622, 2005
15) Nishizawa Y, Shoji T, Nishitani H, et al : Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia : effect of a fibric acid, clinofibrate. Kidney Int 44 : 1352-1359, 1993
16) Mori Y, Hirano T, Nagashima M, et al : Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism 56 : 1714-1718, 2007
17) Shoji T, Nishizawa Y, Nishitani H, et al : Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 41 : 1653-1661, 1992
18) Foley RN, Murray AM, Li S, et al : Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16 : 489-495, 2005
19) Herzog CA, Ma JZ, Collins AJ : Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339 : 799-805, 1998
21) European Association for Cardiovascular Prevention & Rehabilitation1, Reiner Z, Catapano AL, et al : ESC/EAS Guidelines for the management of dyslipidaemias : the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 : 1769-1818, 2011
22) Shastri S, Sarnak MJ : Cardiovascular disease and CKD : core curriculum 2010. Am J Kidney Dis 56 : 399-417, 2010
23) Kasiske BL : Cardiovascular disease after renal transplantation. Semin Nephrol 20 : 176-187, 2000
24) Kasiske BL : Epidemiology of cardiovascular disease after renal transplantation. Transplantation 72 (6 Suppl) : S5-S8, 2001
25) Muntner P, He J, Astor BC, et al : Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease : results from the atherosclerosis risk in communities study. J Am Soc Nephrol 16 : 529-538, 2005
28) Tonelli M, Muntner P, Lloyd A, et al : Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol 24 : 979-986, 2013
31) Baigent C, Landray MJ, Reith C, et al ; SHARP Investigators : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. Lancet 377 : 2181-2192, 2011
32) Sonoda M, Shoji T, Kimoto E, et al : Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus. J Atheroscler Thromb 21 : 346-354, 2014
34) Pradhan AD, Paynter NP, Everett BM, et al : Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J 206 : 80-93, 2018
P.238 掲載の参考文献
1) Stary HC, Chandler AB, Dinsmore RE, et al : A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Arterioscler Thromb Vasc Biol 15 : 1512-1531, 1995
2) 和田隆志, 湯澤由紀夫 (監) : 糖尿病性腎症と高血圧性腎硬化症の病理診断への手引き, p40-60, 東京医学社, 東京, 2015
3) Hommos MS, Glassock RJ, Rule AD : Structural and functional changes in human kidneys with healthy aging. J Am Soc Nephrol 28 : 2838-2844, 2017
4) Smith SM, Hoy WE, Cobb L : Low incidence of glomerulosclerosis in normal kidneys. Arch Pathol Lab Med 113 : 1253-1255, 1989
5) Nigwekar SU, Thadhani R, Brandenburg VM : Calciphylaxis. N Engl J Med 378 : 1704-1714, 2018
P.242 掲載の参考文献
1) XX. Blue toe syndrome. 末梢閉塞性動脈疾患の治療ガイドライン. Circ J 73 (Suppl III) : 1555-1556, 2009
2) Hiramoto J, Hansen KJ, Pan XM, et al : Atheroemboli during renal artery angioplasty : an ex vivo study. J Vasc Surg 41 : 1026-1030, 2005
3) Tunick PA, Perez JL, Kronzon I : Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med 115 : 423-427, 1991
4) Koga J, Ohno M, Okamoto K, et al : Cholesterol embolization treated with corticosteroids--two case reports. Angiology 56 : 497-501, 2005
5) Tamura K, Umemura M, Yano H, et al : Acute renal failure due to cholesterol crystal embolism treated with LDL apheresis followed by corticosteroid and candesartan. Clin Exp Nephrol 7 : 67-71, 2003
P.245 掲載の参考文献
1) Modi KS, Rao VK : Atheroembolic renal disease. J Am Soc Nephrol 12 : 1781-1787, 2001
2) Carvajal JA, Anderson WR, Weiss L, et al : Atheroembolism. An etiologic factor in renal insufficiency, gastrointestinal hemorrhages, and peripheral vascular diseases. Arch Intern Med 119 : 593-599, 1967
3) McGowan JA, Greenberg A : Cholesterol atheroembolic renal disease. Report of 3 cases with emphasis on diagnosis by skin biopsy and extended survival. Am J Nephrol 6 : 135-139, 1986
4) Panum : Experimentell Beitrage zur Lehre von der Embolie. Virchows Arch 25 : 308-310, 1862
5) Flory CM : Arterial Occlusions produced by emboli from eroded aortic atheromatous plaques. Am J Pathol 21 : 549-565, 1945
8) Komatsu S, Yutani C, Ohara T, et al : Angioscopic evaluation of spontaneously ruptured aortic plaques. J Am Coll Cardiol 71 : 2893-2902, 2018
11) Greenberg A, Bastacky SI, Iqbal A, et al : Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism : clinicopathological correlations. Am J Kidney Dis 29 : 334-344, 1997
12) Goldman M, Thoua Y, Dhaene M, et al : Necrotising glomerulonephritis associated with cholesterol microemboli. Br Med J 290 : 205-206, 1985
14) 岡真知子, 岡本好司, 守矢英和, 他 : ステロイド投与とLDL吸着療法の併用により腎機能の改善を認めた腎コレステロール塞栓症 (CCE) の2例. Therapeutic Research 26 : 1805-1806, 2005
P.249 掲載の参考文献
1) Ikejiri M, Wada H, Yamada N, et al : High prevalence of congenital thrombophilia in patients with pregnancy-related or idiopathic venous thromboemboism/pulmonary embolism. Int J Hematol 105 : 272-279, 2017
2) Wada H, Kobayashi T, Abe Y, et al : Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost 4 : 1253-1258, 2006
3) 北村健一郎 : 腎の血管障害. 矢崎義雄 (総編集) : 内科学 第11版, pp1466-1470, 朝倉書店, 東京, 2017

第4章 血圧異常

P.254 掲載の参考文献
1) Shan Z, Shi P, Cuadra AE, et al : Involvement of the brain (pro) renin receptor in cardiovascular homeostasis. Circ Res 107 : 934-938, 2010
2) Li W, Peng H, Mehaffey EP, et al : Neuron-specific (pro) renin receptor knockout prevents the development of salt-sensitive hypertension. Hypertension 63 : 316-323, 2014
3) Li W, Peng H, Cao T, et al : Brain-targeted (pro) renin receptor knockdown attenuates angiotensin II-dependent hypertension. Hypertension 59 : 1188-1194, 2012
4) Huang XB, Tang WW, Liu Y, et al : Prevalence of diabetes and unrecognized diabetes in hypertensive patients aged 40 to 79 years in southwest China. PLoS One 12 : e0170250, 2017
5) Shibayama Y, Fujimori T, Nguyen G, et al : (Pro) renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Sci Rep 5 : 8854, 2015
P.258 掲載の参考文献
2) 日本高血圧学会高血圧治療ガイドライン作成委員会 : 高血圧治療ガイドライン 2019, 2019
3) Kwakernaak AJ, Krikken JA, et al ; Holland Nephrology Study Group : Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy : a randomised clinical trial. Lancet Diabetes Endocrinol 2 : 385-395, 2014
4) Orth SR : Smoking and the kidney. J Am Soc Nephrol 13 : 1663-1672, 2002
5) Afkarian M, Zelnick LR, Hall YN, et al : Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316 : 602-610, 2016
P.262 掲載の参考文献
1) 高血圧緊急症および切迫症の診断と治療. 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 高血圧治療ガイドライン 2014, pp108-112, 2014
2) Chobanian AV, et al ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute ; National High Blood Pressure Education Program Coordinating Committee : Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 : 1206-1252, 2003
3) Osaki Y, Matsubayashi K, Yamasaki M, et al : Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. Hypertens Res 21 : 169-173, 1998
4) 妊娠高血圧症候群新定義・臨床分類 (http://www.jsshp.jp/journal/pdf/20180625_teigi_kaiteian.pdf)
P.266 掲載の参考文献
1) Elliott WJ : Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis 48 : 316-325, 2006
2) Van den Born BJ, Koopmans RP, van Montfrans GA : The renin-angiotensin system in malignant hypertension revisited : plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens 20 : 900-906, 2007
3) Rubin S, Cremer A, Boulestreau R, et al : Malignant hypertension : diagnosis, treatment and prognosis with experience from the Bordeaux cohort. J Hypertens 37 : 316-324, 2019
4) Amraoui F, Bos S, Vogt L, et al : Long-term renal outcome in patients with malignant hypertension : a retrospective cohort study. BMC Nephrol 13 : 71, 2012
5) Gonzalez R, Morales E, Segura J, et al : Long-term renal survival in malignant hypertension. Nephrol Dial Transplant 25 : 3266-3272, 2010
6) Liang S, Le W, Liang D, et al : Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis : a retrospective cohort study. BMC Nephrol 17 : 42, 2016
7) Olson JL : Renal disease caused by hypertension. Heptinstall's Pathology of the Kidney, 7th Edn, pp849-896, Lippincott Williams and Wilkins, Philadelphia, 2015
8) 和田隆志, 湯澤由紀夫 (監) : 糖尿病性腎症と高血圧性腎硬化症の病理診断への手引き, 東京医学社, 東京, 2015
9) Timmermans SAMEG, Abdul-Hamid MA, Vanderlocht J, et al : Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 91 : 1420-1425, 2017
10) Timmermans SAMEG, Abdul-Hamid MA, Potjewijd J, et al : C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension. J Am Soc Nephrol 29 : 2234-2243, 2018
P.270 掲載の参考文献
1) Richards JB, Wilcox SR : Diagnosis and management of shock in the emergency department. Emerg Med Pract 16 : 1-22, 2014
2) 太田智行, 西岡真樹子, 中田典生, 他 : Focused ultrasound examination (的を絞った超音波検査) は日本で普及するか. 日臨救急医会誌 20 : 499-507, 2017
3) Cannon JW : Hemorrhagic shock. N Engl J Med 378 : 370-379, 2018
4) 日本版敗血症診療ガイドライン2016作成特別委員会 (編) : 日本版敗血症診療ガイドライン 2016 (J-SSCG2016), 真興交易医書出版部, 東京, 2017
5) Hagen EM : Acute complications of spinal cord injuries. World J Orthop 6 : 17-23, 2015
P.272 掲載の参考文献
1) AKI (急性腎障害) 診療ガイドライン作成委員会 (編) : AKI (急性腎障害) 診療ガイドライン 2016, 東京医学社, 東京, 2016
2) Blantz RC : Pathophysiology of pre-renal azotemia. Kidney Int 53 : 512-523, 1998
3) Whiting P, Morden A, Horwood J, et al : What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open 7 : e012674, 2017

第5章 血液疾患

P.277 掲載の参考文献
2) 松本雅則, 藤村吉博, 和田英夫, 他 : 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2017. 臨床血液 58 : 271-281, 2017
3) Scully M, Cataland S, Coppo P, et al : Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15 : 312-322, 2017
4) 香美祥二, 岡田浩一, 南学正臣, 他 : 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015. 日腎会誌 58 : 62-75, 2016
5) Rock GA, Shumak KH, Buskard NA, et al : Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325 : 393-397, 1991
P.283 掲載の参考文献
4) Asif A, Nayer A, Haas CS : Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions : case reports and a review of the evidence for treatment with eculizumab. J Nephrol 30 : 347-362, 2017
5) 三井亜希子, 清水章 : TMAの病理組織. 日腎誌 56 : 1029-1030, 2014
6) Kitiyakara C, Guzman NJ : Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 9 : 133-142, 1998
7) Espinosa G, Bucciarelli S, Cervera R, et al : Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 63 : 730-736, 2004
8) Markowitz GS, Bomback AS, Perazella MA : Drug-induced glomerular disease : direct cellular injury. Clin J Am Soc Nephrol 10 : 1291-1299, 2015
9) Bennett CL, Kim B, et al ; SERF-TTP Research Group : Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura : a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 50 : 1138-1143, 2007
10) Grace AA, Barradas MA, Mikhaillidis DP, et al : Cyclosporin A enhances platelet aggregation. Kidney Int 32 : 889-895, 1987
11) Izzedine H, Perazella MA : Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66 : 857-868, 2015
12) Krishnappa V, Gupta M, Shah H, et al : The use of eculizumab in gemcitabine induced thrombotic microangiopathy. BMC Nephrol 19 : 9, 2018
13) Eremina V, Jefferson JA, Kowalewska J, et al : VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 : 1129-1136, 2008
14) Fakhouri F, Roumenina L, Provot F, et al : Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21 : 859-867, 2010
15) Laskin BL, Goebel J, Davies SM, et al : Small vessels, big trouble in the kidneys and beyond : hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 118 : 1452-1462, 2011
16) Mii A, Shimizu A, Kaneko T, et al : Renal thrombotic microangiopathy after hematopoietic stem cell transplantation : involvement of chronic graft-versus-host disease. Kidney Int Rep 3 : 743-747, 2018
P.286 掲載の参考文献
2) Jiang H, An X, Li Y, et al : Clinical features and prognostic factors of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus : a literature review of 105 cases from 1999 to 2011. Clin Rheumatol 33 : 419-427, 2014
3) Vasoo S, Thumboo J, Fong KY : Thrombotic thrombocytopenic purpura in systemic lupus erythematosus : disease activity and the use of cytotoxic drugs. Lupus 11 : 443-450, 2002
4) Bose N, Chiesa-Vottero A, Chatterjee S : Scleroderma renal crisis. Semin Arthritis Rheum 44 : 687-694, 2015
5) Steen VD : Scleroderma renal crisis. Rheum Dis Clin North Am 22 : 861-878, 1996
P.289 掲載の参考文献
1) 溶血性尿毒症症候群の診断・治療ガイドライン (http://www.jspn.jp/file/pdf/20140618_guideline.pdf)
2) Orth D, Khan AB, Naim A, et al : Shiga toxin activates complement and binds factor H : evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182 : 6394-6400, 2009
3) Ehrlenbach S, Rosales A, Posch W, et al : Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 81 : 2678-2685, 2013
4) Hickey CA, Beattie TJ, Cowieson J, et al : Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 165 : 884-889, 2012
5) Ardissino G, Tel F, Possenti I, et al : Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 137 : 2015-2153, 2016
6) Takanashi J, Taneichi H, Misaki T, et al : Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology 82 : 564-572, 2014
7) Honda T, Ogata S, Mineo E, et al : A novel strategy for hemolytic uremic syndrome : successful treatment with thrombomodulin α. Pediatrics 131 : e928-e933, 2013
8) Suyama K, Kawasaki Y, Miyazaki K, et al : The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice. Nephrol Dial Transplant 30 : 969-977, 2015
9) Safdar N, Said A, Gangnon RE, et al : Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157 : H7 enteritis : a meta-analysis. JAMA 288 : 996-1001, 2002
P.294 掲載の参考文献
1) Masias C, Vasu S, Cataland SR : None of the above : thrombotic microangiopathy beyond TTP and HUS. Blood 129 : 2857-2863, 2017
2) Scully M, Goodship T : How I treat thrombotic thrombocytopenic purpura and atypical hemolytic uraemic syndrome. Br J Haematol 164 : 759-766, 2014
3) Scully M, Cataland S, Coppo P, et al : Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thoromb Haemost 15 : 312-322, 2017
4) 宮川義隆 : aHUSの治療. 宮川義隆, 松本雅則, 南学正臣 (編) : 血栓性微小血管症 (TMA) 診断・治療実践マニュアル, 医薬ジャーナル社, 大阪, 2016
P.298 掲載の参考文献
1) Fujisawa M, Kato H, Yoshida Y, et al : Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 22 : 1088-1099, 2018
2) Jokiranta TS : HUS and atypical HUS. Blood 129 : 2847-2856, 2017
3) Legendre CM, Licht C, Muus P, et al : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 : 2169-2181, 2013
4) Fakhouri F, Zuber J, Fremeaux-Bacchi V, et al : Haemolytic uraemic syndrome. Lancet 390 : 681-696, 2017
5) Noris M, Caprioli J, Bresin E, et al : Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5 : 1844-1859, 2010
P.301 掲載の参考文献
1) Watanabe O, Arimura K, Kitajima I, et al : Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347 : 702, 1996
2) Abe D, Nakaseko C, Takeuchi M, et al : Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112 : 836-839, 2008
3) Dispenzieri A : POEMS syndrome : 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92 : 814-829, 2017
4) Ohwada C, Sakaida E, Kawajiri-Manako C, et al : Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood 131 : 2173-2176, 2018
5) Misawa S, Sato Y, Katayama K, et al : Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15 : 1129-1137, 2016
P.306 掲載の参考文献
1) Nakamoto Y, Imai H, Yasuda T, et al : A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 14 : 2370-2378, 1999
2) Nakamura Y, Nishimura M, Terano T, et al : A patient with POEMS syndrome : the pathology of glomerular microangiopathy. Tohoku J Exp Med 231 : 229-234, 2013
3) Ye W, Wang C, Cai QQ, et al : Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome : incidence, treatment and outcome. Nephrol Dial Transplant 31 : 275-283, 2016
4) Higashi AY, Nogaki F, Kato I, et al : Serial renal biopsy findings in a case of POEMS syndrome with recurrent acute renal failure. Clin Exp Nephrol 16 : 173-179, 2012
5) Kihara Y, Hori H, Murakami H, et al : A case of POEMS syndrome associated with reactive amyloidosis and Waldenstrom's macroglobulinaemia. J Intern Med 252 : 255-258, 2002
6) Wang Y, Yan Y, Sui Z, et al : A case report of POEMS syndrome with renal involvement as immunotactoid glomerulopathy. Medicine (Baltimore) 97 : e9920, 2018
P.309 掲載の参考文献
1) Fajgenbaum DC, Uldrick TS, Bagg A, et al : International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129 : 1646-1657, 2017
2) Fajgenbaum DC, van Rhee F, Nabel CS : HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood 123 : 2924-2933, 2014
3) Fujimoto S, Koga T, Kawakami A, et al : Tentative diagnostic criteria and disease severity classification for Castleman disease : a report of the research group on Castleman disease in Japan. Mod Rheumatol 28 : 161-167, 2018
4) Masaki Y, Kawabata H, Takai K, et al : Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 103 : 686-692, 2016
5) Kurose N, Futatsuya C, Mizutani KI, et al : The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Hum Pathol 77 : 130-138, 2018
P.311 掲載の参考文献
1) El Karoui K, Vuiblet V, Dion D, et al : Renal involvement in Castleman disease. Nephrol Dial Transplant 26 : 599-609, 2011
2) Xu D, LvJ, Dong Y, et al : Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant 27 (Suppl 3) : iii119-iii125, 2012
3) Matsunami M, Ubara Y, Sumida K, et al : The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease : early post-transplant outcome. BMC Nephrol 19 : 263, 2018
4) Noda-Narita S, Sumida K, Sekine A, et al : TAFRO syndrome with refractory thrombocytopenia responding o tocilizumab and romiplostim : a case report. CEN Case Rep 7 : 162-168, 2018
5) Mizuno H, Sekine A, Oguro M, et al : Renal histology in a patient with TAFRO syndrome : a case report. Hum Pathol 82 : 258-263, 2018
P.315 掲載の参考文献
1) Rajkumar SV, Dimopoulos MA, Palumbo A, et al : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15 : e538-e548, 2014
2) Palumbo A, Avet-Loiseau H, Oliva S, et al : Revised International Staging System for multiple myeloma : a report from International Myeloma Working Group. J Clin Oncol 33 : 2863-2869, 2015
3) 日本血液学会 (編) : 造血器腫瘍診療ガイドライン 2018年版, 金原出版, 東京, 2018
4) Dimopoulos MA, Sonneveld P, Leung N, et al : International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34 : 1544-1557, 2016
5) Ozaki S, Handa H, Saitoh T, et al : Trends of survival in patients with multiple myeloma in Japan : a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 5 : e349, 2015
P.319 掲載の参考文献
1) 日本血液学会 : 造血器腫瘍診療ガイドライン 2018, 2018
2) Fava A, Fulladosa X, Montero N, et al : Treatment of multiple myeloma with renal involvement : the nephrologist's view. Clin Kidney J 11 : 777-785, 2018
3) Korbet SM, Schwartz MM : Multiple myeloma. J Am Soc Nephrol 17 : 2533-2545, 2006
4) Ganeval D, Rabian C, Guerin V, et al : Treatment of multiple myeloma with renal involvement. Adv Nephrol Necker Hosp 21 : 347-370, 1992
5) Montseny JJ, Kleinknecht D, Meyrier A, et al : Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 13 : 1438-1445, 1998
6) Knudsen LM, Hippe E, Hjorth M, et al : Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 53 : 207-212, 1994
7) Decourt C, Rocca A, Bridoux F, et al : Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 94 : 3559-3566, 1999
8) Rota S, Mougenot B, Baudouin B, et al : Multiple myeloma and severe renal failure : a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 60 : 126-137, 1987
9) Sanders PW : Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 124 : 484-488, 1994
10) Rayner HC, Haynes AP, Thompson JR, et al : Perspectives in multiple myeloma : survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med 79 : 517-525, 1991
11) Durie BG, Kyle RA, Belch A, et al : Myeloma management guidelines : a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4 : 379-398, 2003
12) Markowitz GS, Fine PL, Stack JI, et al : Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64 : 281-289, 2003
13) Dimopoulos MA, Richardson PG, Schlag R, et al : VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment : cohort analysis of the phase III VISTA study. J Clin Oncol 27 : 6086-6093, 2009
14) Ludwig H, Adam Z, Hajek R, et al : Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma : results of a phase II study. J Clin Oncol 28 : 4635-4641, 2010
15) Roussou M, Kastritis E, Christoulas D, et al : Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34 : 1395-1397, 2010
16) Clark WF, Stewart AK, Rock GA, et al : Plasma exchange when myeloma presents as acute renal failure : a randomized, controlled trial. Ann Intern Med 143 : 777-784, 2005
17) アミロイド診療ガイドライン 2010, 2010
18) Teng J, Russell WJ, Gu X, et al : Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 84 : 440-451, 2004
19) Kyle RA : Treatment of chain amyloidosis (AL). Adv Nephrol Necker Hosp 28 : 383-399, 1998
20) Gertz MA, Kyle RA : Prognostic value of urinary protein in primary systemic amyloidosis (AL). Am J Clin Pathol 94 : 313-317, 1990
21) Kyle RA, Gertz MA, Greipp PR, et al : A trial of three regimens for primary amyloidosis : colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336 : 1202-1207, 1997
22) Casserly LF, Fadia A, Sanchorawala V, et al : High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 63 : 1051-1057, 2003
23) Doshi M, Lahoti A, Danesh FR, et al : Paraprotein-Related Kidney Disease : Kidney Injury from Paraproteins-What Determines the Site of Injury? Clin J Am Soc Nephrol 11 : 2288-2294, 2016
24) Lin J, Markowitz GS, Valeri AM, et al : Renal monoclonal immunoglobulin deposition disease : the disease spectrum. J Am Soc Nephrol 12 : 1482-1492, 2001
25) Pozzi C, D'Amico M, Fogazzi GB, et al : Light chain deposition disease with renal involvement : clinical characteristics and prognostic factors. Am J Kidney Dis 42 : 1154-1163, 2003
26) Heilman RL, Velosa JA, Holley KE, et al : Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20 : 34-41, 1992
P.324 掲載の参考文献
1) McKenna RW, Kyle RA, Kuehl WM, et al : Plasma cell neoplasms : Swerdlow SH, Campo E, Harris NL, et al (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised 4th Edn, pp241-265, IARC, Lyon, 2017
2) Kumar S, Dispenzieri A, Lacy MQ, et al : Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30 : 989-995, 2012
3) 日本血液学会 : ALアミロイドーシス. 日本血液学会 (編) : 造血器腫瘍ガイドライン 2018年版, pp371-375, 金原出版, 東京, 2018
4) Palladini G, Dispenzieri A, Gertz MA, et al : New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers : impact on survival outcomes. J Clin Oncol 30 : 4541-4549, 2012
5) Palladini G, Hegenbart U, Milani P, et al : A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124 : 2325-2332, 2014
P.327 掲載の参考文献
1) Milani P, Merlini G, Palladini G : Novel therapies in light chain amyloidosis. Kidney Int Rep 3 : 530-541, 2017
2) 西村名帆子, 今井裕一 : 免疫機能異常に由来する疾患. AL型腎アミロイドーシス. 臨牀透析 32 : 421-428, 2016
3) Suga N, Miura N, Kitagawa W, et al : Differential diagnosis of localized and systemic amyloidosis based on coagulation and fibrinolysis parameters. Amyloid 19 : 61-65, 2012
4) Palladini G, Milani P, Foli A, et al : Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis : long-term results of a risk-adapted approach. Haematologica 99 : 743-750, 2014
5) Palladini G, Hegenbart U, Milani P, et al : A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124 : 2325-2332, 2014
P.332 掲載の参考文献
2) Leung N, Bridoux F, Hutchison CA, et al : Monoclonal gammopathy of renal significance : when MGUS is no longer undetermined or insignificant. Blood 120 : 4292-4295, 2012
3) Fish R, Pinney J, Jain P, et al : The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 5 : 1977-1980, 2010
4) Steiner N, Gobel G, Suchecki P, et al : Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma : an observational study of 2935 MGUS patients. Oncotarget 9 : 2344-2356, 2018
5) Kourelis TV, Nasr SH, Dispenzieri A, et al : Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol 91 : 1123-1128, 2016
6) Cohen C, Royer B, Javaugue V, et al : Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88 : 1135-1143, 2015
P.336 掲載の参考文献
1) Leung N, Bridoux F, Hutchison CA, et al : Monoclonal gammopathy of renal significance : when MGUS is no longer undetermined or insignificant. Blood 120 : 4292-4295, 2012
2) Leung N, Bridoux F, Batuman V, et al : The evaluation of monoclonal gammopathy of renal significance : a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 15 : 45-59, 2019
3) Comenzo RL, Reece D, Palladini G, et al : Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26 : 2317-2325, 2012
4) Cohen C, Royer B, Javaugue V, et al : Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88 : 1135-1143, 2015
5) Fermand JP, Bridoux F, Kyle RA, et al : How I treat monoclonal gammopathy of renal significance (MGRS). Blood 122 : 3583-3590, 2013
P.340 掲載の参考文献
1) Ohtake S, Miyawaki S, Fujita H, et al : Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia : the JALSG AML201 Study. Blood 117 : 2358-2365, 2011
2) Huguet F, Leguay T, Raffoux E, et al : Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : the GRAALL-2003 study. J Clin Oncol 27 : 911-918, 2009
3) Hatta Y, Mizuta S, Matsuo K, el al : Final analysis of the JALSG Ph+ALL202 study : tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Ann Hematol 97 : 1535-1545, 2018
P.343 掲載の参考文献
1) Galloway J : Remarks on Hodgkin's disease. Br Med J 2 : 1201-1208, 1922
3) Cairo MS, Coiffier B, Reiter A, et al ; TLS Expert Panel : Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases : an expert TLS panel consensus. Br J Haematol 149 : 578-586, 2010
4) Pettitt AR, Clark RE : Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 14 : 495-504, 1994
5) Kuhlmann MK, Burkhardt G, Kohler H : Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12 : 2478-2480, 1997
P.346 掲載の参考文献
1) Parker C, Omine M, Richards S, et al : Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106 : 3699-3709, 2005
2) 日本腎臓学会 (編) : CKD診療ガイド 2012, 東京医学社, 東京, 2012
3) Moreno JA, Martin-Cleary C, Gutierrez E, et al : AKI associated with macroscopic glomerular hematuria : clinical and pathophysiologic consequences. Clin J Am Soc Nephrol 7 : 175-184, 2012
4) Benigni A, Morigi M, Perico N, et al : The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation 54 : 775-780, 1992
5) Kanakura Y, Ohyashiki K, Shichishima T, et al : Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria : the AEGIS clinical trial. Int J Hematol 93 : 36-46, 2011
6) Kanakura Y, Ohyashiki K, Shichishima T, et al : Long-term efficacy and safety of eculizumab in Japanese patients with PNH : AEGIS trial. Int J Hematol 98 : 406-416, 2013
7) Ninomiya H, Obara N, Chiba S, et al : Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol 104 : 548-558, 2016
8) Hillmen P, Elebute M, Kelly R, et al : Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85 : 553-559, 2010
9) Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83 : 193-207, 2004
P.349 掲載の参考文献
1) Ninomiya H, Obara N, Chiba S, et al : Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol 104 : 548-558, 2016
2) Schubert J, Roth A : Update on paroxysmal nocturnal haemoglobinuria : on the long way to understand the principles of the disease. Eur J Haematol 94 : 464-473, 2015
3) Hillmen P, Muus P, Duhrsen U, et al : Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110 : 4123-4128, 2007
4) Iki S, Ohgi K, Suzuki K : Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria. Int J Hematol 105 : 231-232, 2017
5) Yamada Y, Abe R, Okano Y, et al : Long-term eculizumab treatment contributes to recovery from end-stage renal disease caused by atypical hemolytic uremic syndrome. Intern Med 56 : 1085-1088, 2017
P.353 掲載の参考文献
1) Audard V, Zhang SY, Copie-Bergman C, et al : Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes. Blood 115 : 3756-3762, 2010
2) Malbrain ML, Lambrecht GL, Daelemans R, et al : Acute renal failure due to bilateral lymphomatous infiltrates. Primary extranodal non-Hodgkin's lymphoma (p-EN-NHL) of the kidneys : does it really exist? Clin Nephrol 42 : 163-169, 1994
3) Desclaux A, Lazaro E, Pinaquy JB, et al : Renal intravascular large B-cell lymphoma : a case report and review of the literature. Intern Med 56 : 827-833, 2017
P.357 掲載の参考文献
1) 朝倉英策 : 播種性血管内凝固症候群 (DIC). 朝倉英策 (編) : 臨床に直結する血栓止血学改訂2版, pp286-299, 中外医学社, 東京, 2018
3) 朝倉英策 : 播種性血管内凝固症候群. 日本血液学会 (編) : 血液専門医テキスト, pp366-369, 南江堂, 東京, 2011
4) 朝倉英策 : 日本血栓止血学会DIC診断基準 2017年版. 朝倉英策 (編) : 臨床に直結する血栓止血学改訂2版, pp300-308, 中外医学社, 東京, 2018
5) 和田英夫, 野間桂 : 本邦のエキスパートコンセンサス. 救急・集中治療 26 : 781-786, 2014
6) 野村昌作 : 止血系マーカーと治療効果の関係. 尾崎由基男, 和田英夫 (監) : DIC~とびらを拓く第三世代へ~, pp188-193, 克誠堂出版, 東京, 2011
7) 野村昌作 : 造血器腫瘍に伴うDICに対するトロンボモジュリンの治療効果. 日本検査血液学会雑誌 11 : 235-241, 2010
8) Ikezoe T : Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. Int J Hematol 100 : 27-37, 2014
9) Ito T, Kawahara K, Okamoto K, et al : Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28 : 1825-1830, 2008

第6章 感染症

P.364 掲載の参考文献
1) 国立感染症研究所 : A 群溶血性レンサ球菌咽頭炎Group A streptococcal pharyngitis (https://www.niid.go.jp/niid/ja/10/2096-weeklygraph/1646-03strepta.html)
2) Roggen I, van Berlaer G, Gordts F, et al : Centor criteria in children in a paediatric emergency department : for what it is worth. BMJ Open 3 : e002712, 2013
3) Shulman ST, Bisno AL, Clegg HW, et al : Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis : 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 55 : 1279-1282, 2012
4) Cohen JF, Bertille N, Cohen R, et al : Rapid antigen detection test for group A streptcoccus in children with pharyngitis. Cochrane Database Syst Rev 7 : CD010502, 2016
5) Lennon D, Kerdemelidis M, Arroll B : Meta-analysis of trials of streptococcal throat treatment programs to prevent rheumatic fever. Pediatr Infect Dis J 28 : e259-e264, 2009
P.368 掲載の参考文献
1) 尾田高志 : 感染関連糸球体腎炎に関する最近の知見. 東医大誌 73 : 355-363, 2015
3) Chang JF, Peng YS, Tsai CC, et al : A possible rare cause of renal failure in streptococcal infection. Nephrol Dial Transplant 26 : 368-371, 2011
5) Vernon KA, Goicoechea de Jorge E, Hall AE, et al : Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 60 : 121-125, 2012
P.371 掲載の参考文献
1) 日本化学療法学会・日本感染症学会MRSA感染症の治療ガイドライン作成委員会 (編) : MRSA感染症の治療ガイドライン 2017年改訂版, 2017
2) 厚生労働省 : 院内感染対策サーベイランス事業 (https://janis.mhlw.go.jp/index.asp)
3) 河村一郎, 関谷紀貴, 荒岡秀樹, 他 : 7施設におけるメチシリン耐性黄色ブドウ球菌サーベイランス (2015年度). 環境感染誌 32 : 135-140, 2017
4) 日本化学療法学会・日本TDM 学会 ; 抗菌薬TDMガイドライン作成委員会 (編) : 抗菌薬TDMガイドライン 2016, 2016
5) Jacob JT, DiazGranados CA : High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections : a meta-analysis. Int J Infect Dis 17 : e93-e100, 2013
P.375 掲載の参考文献
2) Boils CL, Nasr SH, Walker PD, et al : Update on endocarditis-associated glomerulonephritis. Kidney Int 87 : 1241-1249, 2015
3) Neugarten J, Baldwin DS : Glomerulonephritis in bacterial endocarditis. Am J Med 77 : 297-304, 1984
5) White J, Herman A, Pullen AM, et al : The Vβ-specific superantigen staphylococcal enterotoxin B : stimulation of mature T cells and clonal deletion in neonatal mice. Cell 56 : 27-35, 1989
6) Dellabona P, Peccorud J, Kappler J, et al : Superantigens interact with MHC class II molecules outside of the antigen groove. Cell 62 : 1115-1121, 1990
7) Herman A, Kappler J, Marrack P, et al : Superantigens : mechanism of T-cell stimulation and role in immune responses. Annu Rev Immunol 9 : 745-772, 1991
8) Hirayama K, Kobayashi M, Muro K, et al : Specific T-cell receptor usage with cytokinemia in Henoch-Schonlein purpura nephritis associated with Staphylococcus aureus infection. J Intern Med 249 : 289-295, 2001
9) Yoh K, Kobayashi M, Yamaguchi N, et al : Cytokines and T-cell responses in superantigen-related glomerulonephritis following methicillin-resistant Staphylococcus aureus infection. Nephrol Dial Transplant 15 : 1170-1174, 2000
10) Nasr SH, Markowitz GS, Whelan JD, et al : IgA-dominant acute poststaphylococcal glomerulonephritis complicating diabetic nephropathy. Hum Pathol 34 : 1235-1241, 2003
11) Koyama A, Sharmin S, Sakurai H, et al : Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int 66 : 121-132, 2004
12) Sharmin S, Shimizu Y, Hagiwara M, et al : Staphylococcus aureus antigens induce IgA-type glomerulonephritis in Balb/c mice. J Nephrol 17 : 504-511, 2004
13) Bu R, Li Q, Duan ZY, et al : Clinicopathologic features of IgA-dominant infection-associated glomerulonephritis : a pooled analysis of 78 cases. Am J Nephrol 41 : 98-106, 2015
14) Nasr SH, D'Agati VD : IgA-dominant postinfectious glomerulonephritis : a new twist on an old disease. Nephron Clin Pract 119 : c18-c26, 2011
15) Haas M, Racusen LC, Bagnasco SM : IgA-dominant postinfectious glomerulonephritis : a report of 13 cases with common ultrastructural features. Hum Pathol 39 : 1309-1316, 2008
16) Okuyama S, Wakui H, Maki N, et al : Successful treatment of post-MRSA infection glomerulonephritis with steroid therapy. Clin Nephrol 70 : 344-347, 2008
17) Nagaba Y, Hiki Y, Aoyama T, et al : Effective antibiotic treatment of methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron 92 : 297-303, 2002
P.379 掲載の参考文献
1) 武田修明 : エルシニア感染症. 小児科診療 64 : 1030-1035, 2001
2) 武田修明 : エルシニア感染症の多彩な症状と合併症. 小児感染免疫 29 : 67-72, 2017
3) 米国小児科学会 (編), 岡部信彦 (監) : エンテロコリチカ菌と偽結核菌感染. 最新感染症ガイドR-book 2015, pp868-870, 日本小児医事出版社, 東京, 2016
4) Abe J, Onimaru M, Matsumoto S, et al : Clinical role for a superantigen in Yersinia pseudotuberculosis infection. J Clin Invest 99 : 1823-1830, 1997
5) 武田修明 : 感染症に伴う腎障害. 日本小児腎臓病学会 (編) : 小児腎臓病学, pp328-330, 診断と治療社, 東京, 2012
P.383 掲載の参考文献
1) Abe J, Takeda T, Watanabe Y, et al : Evidence for superantigen production by Yersinia pseudotuberculosis. J Immunol 151 : 4183-4188, 1993
2) Uchiyama T, Miyoshi-Akiyama T, Kato H, et al : Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute and systemic symptoms. J Immunol 151 : 4407-4413, 1993
3) 武田修明, 西田吉伸, 小西央郎, 他 : エルシニア感染症の臨床的検討. 小児科臨床 58 : 297-301, 1995
4) 石川智朗, 宮園明典, 佐藤舞, 他 : エルシニア間質性腎炎の診断における抗YPM抗体の有用性. 日児腎誌 25 : 258, 2012
5) 阿部淳 : エルシニア感染症とスーパー抗原. 医のあゆみ 193 : 887-890, 2000
6) 深山雄大, 和田尚弘, 鵜野裕一, 他 : Yersinia pseudotuberculosis感染による急性尿細管間質性腎炎リスクファクターの検討. 日児腎誌 26 : 187-193, 2013
P.386 掲載の参考文献
1) Gordon AC, Mason AJ, Thirunavukkarasu N, et al : Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock : The VANISH Randomized Clinical Trial. JAMA 316 : 509-518, 2016
2) Prowle JR, Ishikawa K, May CN, et al : Renal blood flow during acute renal failure in man. Blood Purif 28 : 216-225, 2009
3) Joannidis M, Druml W, Forni LG, et al : Prevention of acute kidney injury and protection of renal function in the intensive care unit : update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med 43 : 730-749, 2017
P.390 掲載の参考文献
2) Nisula S, Kaukonen KM, Vaara ST, et al : Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units : the FINNAKI study. Intensive Care Med 39 : 420-428, 2013
4) Wald R, Quinn RR, Adhikari NK, et al : Risk of chronic dialysis and death following acute kidney injury. Am J Med 125 : 585-593, 2012
5) Bellomo R, Kellum JA, Ronco C, et al : Acute kidney injury in sepsis. Intensive Care Med 43 : 816-828, 2017
6) Gustot T : Multiple organ failure in sepsis : prognosis and role of systemic inflammatory response. Curr Opin Crit Care 17 : 153-159, 2011
7) Maiden MJ, Otto S, Brealey JK, et al : Structure and function of the kidney in septic shock. A prospective controlled experimental study. Am J Respir Crit Care Med 194 : 692-700, 2016
8) Haase M, Devarajan P, Haase-Fielitz A, et al : The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury : a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 57 : 1752-1761, 2011
9) Doi K, Noiri E, Maeda-Mamiya R, et al : Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med 38 : 2037-2042, 2010
10) Basu RK, Wang Y, Wong HR, et al : Incorporation of biomarkers with the renal angina index for prediction of severe AKI in critically ill children. Clin J Am Soc Nephrol 9 : 654-662, 2014
11) Matsuura R, Srisawat N, Claure-Del Granado R, et al : Use of the Renal Angina Index in determining acute kidney injury. Kidney Int Rep 3 : 677-683, 2018
13) Flechet M, Guiza F, Schetz M, et al : AKI predictor, an online prognostic calculator for acute kidney injury in adult critically ill patients : development, validation and comparison to serum neutrophil gelatinase-associated lipocalin. Intensive Care Med 43 : 764-773, 2017
14) Khanna A, English SW, Wang XS, et al : Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377 : 419-430, 2017
15) Tumlin JA, Murugan R, Deane AM, et al : Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med 46 : 949-957, 2018
P.393 掲載の参考文献
1) 公益財団法人結核予防会 : 新登録患者数および罹患率の年次推移. 公益財団法人結核予防会 : 結核の統計 2018, p27, 公益財団法人結核予防会, 東京, 2018
2) 佐々木ヨリ子, 望月孝二, 重藤えり子 : 国立療養所における肺外結核の発生と治療の現況 (泌尿器結核について) -国療化研第26次B研究報告-. 結核 60 : 9-13, 1985
3) Altiparmak MR, Trabulus S, Balkan II, et al : Urinary tuberculosis : a cohort of 79 adult cases. Ren Fail 37 : 1157-1163, 2015
4) Gibson MS, Puckett ML, Shelly ME : Renal tuberculosis. Radiographics 24 : 251-256, 2004
5) Morales A, Eidinger D, Bruce AW : Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 : 180-183, 1976
6) 福島千尋, 渡邊洋子, 赤穂保 : 東京都多摩地域における血液透析患者の結核発症の現状. 結核 86 : 857-862, 2011
7) 高橋計行, 辻野正隆, 寺下泰成, 他 : 慢性血液透析症例における結核症の臨床的検討. 日腎誌 29 : 1295-1300, 1987
8) 佐々木結花, 山岸文雄, 森亨 : 血液透析患者における結核発病の現状. 結核 77 : 51-59, 2002
9) 日本結核病学会予防委員会・治療委員会 : 潜在性結核感染症治療指針. 結核 88 : 497-512, 2013
10) 日本結核病学会治療委員会 : 肝, 腎障害時の抗結核薬の使用についての見解. 結核 61 : 53-54, 1986
11) Blumberg HM, Burman WJ, Chaisson RE, et al : American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America : treatment of tuberculosis. Am J Respir Crit Care Med 167 : 603-662, 2003
12) British Thoracic Society : Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 65 : 557-570, 2010
P.398 掲載の参考文献
1) Wu VC, Wang CY, Shiao CC, et al : Increased risk of active tuberculosis following acute kidney injury : a nationwide, population-based study. PLoS One 8 : e69556, 2013
2) Xu H, Gasparini A, Ishigami J, et al : eGFR and the risk of community-acquired infections. Clin J Am Soc Nephrol 12 : 1399-1408, 2017
3) Cheng KC, Liao KF, Lin CL, et al : Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy : a cohort study in Taiwan. Medicine (Baltimore) 97 : e12550, 2018
4) Igari H, Imasawa T, Noguchi N, et al : Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis. J Infect Chemother 21 : 559-563, 2015
5) 日本結核病学会 (編) : 結核診療ガイドライン改訂第3版, pp77-96, 南江堂, 東京, 2015
6) Eastwood JB, Corbishley CM, Grange JM : Tuberculosis and the kidney. J Am Soc Nephrol 12 : 1307-1314, 2001
7) 日本透析医学会 : 図説わが国の慢性透析療法の現況 (https://member.jsdt.or.jp/member/contents/cdrom/2017/main.html)
P.401 掲載の参考文献
1) Golden MR, Marra CM, Holmes KK : Update on syphilis : resurgence of an old problem. JAMA 290 : 1510-1514, 2003
2) Zhang Z, Hever A, Bhasin N, et al : Secondary syphilis associated with membranous nephropathy and acute hepatitis in a patient with HIV : a case report. Perm J 22 : 17-62, 2018
3) Lee CT, Lam KK, Liao SC, et al : The significance of syphilis serology tests on long-term hemodialysis patients. Changgeng Yi Xue Za Zhi 21 : 447-452, 1998
4) 性感染症診断・治療ガイドライン 2016. 日本性感染症学会誌 27 (Suppl) : 48-52, 2016 (http://jssti.umin.jp/pdf/guideline-2016_v2.pdf)
5) 池内和彦, 福島一彰, 田中勝, 他 : 梅毒に対するアモキシシリン1,500 mg 内服治療の臨床的効果. 感染症学雑誌 92 : 358-364, 2018
P.405 掲載の参考文献
1) 梅毒. 性感染症診断・治療ガイドライン 2016. 日性感染症会誌 27 : 48-52, 2016
2) 日本性感染症学会梅毒委員会梅毒診療ガイド作成小委員会 (委員長 : 荒川創一) : 梅毒診療ガイド, 厚生労働科学研究「性感染症に関する特定感染症予防指針に基づく対策の推進に関する研究」 (研究代表者 : 三鴨廣繁), http://jssti.umin.jp/pdf/syphilis-medical_guide.pdf (最終アクセス日 ; 2018年12月29日)
3) 池内和彦, 福島一彰, 田中勝, 他 : 梅毒に対するアモキシシリン1,500 mg 内服治療の臨床的効果. 感染症誌 92 : 358-364, 2018
4) Tanizaki R, Nishijima T, Aoki T, et al : High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection. Clin Infect Dis 61 : 177-183, 2015
P.409 掲載の参考文献
1) World Health Organization : Fact sheets. https://www.who.int/news-room/fact-sheets/. Accessed 9 Dec 2018
2) Kehinde EO, Anim JT, Hira PR : Parasites of urological importance. Urol Int 81 : 1-13, 2008
3) Barsoum RS : Parasitic kidney disease : milestones in the evolution of our knowledge. Am J Kidney Dis 61 : 501-513, 2013
4) Barsoum RS. Tropical parasitic nephropathies. Nephrol Dial Transplant 14 (Suppl 3) : 79-91, 1999
5) van Velthuysen ML, Florquin S : Glomerulopathy associated with parasitic infections. Clin Microbiol Rev 13 : 55-66, 2000
P.412 掲載の参考文献
1) Churg J, Bernstein J, Glassock RJ : Chapter 10 Parasitic Glomerulopathies. Renal Disease Classification and Atlas of Glomerular Diseases, Second Edn, IGAKU-SNOIN, 1995
2) Cameron S, et al (eds) : Oxford Textbook of Clinical Nephrology, pp468-468, Oxford Medical Publication, 1992
3) 高橋康一 : 腎寄生虫感染症. 日本臨牀別冊腎臓症候群 (第2版) 下 : 683-687, 2012
4) 国立感染症研究所 : 感染情報センター. マラリア (http://www.nid.go.jp/nid/ja/kansenshonohanashi/519-malaria.html)
5) 原田孝司, 舩越哲 : 熱帯感染症と稀少疾患. 腎と透析 76 : 363-366, 2014
P.415 掲載の参考文献
1) Ekrikpo UE, Kengne AP, Bello AK, et al : Chronic kidney disease in the global adult HIV-infected population : a systematic review and meta-analysis. PLoS One 13 : e0195443, 2018
2) Yanagisawa N, Muramatsu T, Koibuchi T, et al : Prevalence of chronic kidney disease and poor diagnostic accuracy of dipstick proteinuria in human immunodeficiency virus-infected individuals : a multicenter study in Japan. Open Forum Infect Dis 5 : ofy216, 2018
3) Campos P, Ortiz A, Soto K : HIV and kidney diseases : 35 years of history and consequences. Clin Kidney J 9 : 772-781, 2016
4) Kasembeli AN, Duarte R, Ramsay M, et al : APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J Am Soc Nephrol 26 : 2882-2890, 2015
5) Wohl D, Oka S, Clumeck N, et al : Brief report : a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment : week 96 results. J Acquir Immune Defic Syndr 72 : 58-64, 2016
P.418 掲載の参考文献
1) Lohse N, Hansen AB, Pedersen G, et al : Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146 : 87-95, 2007
2) 村松崇, 柳澤如樹, 近澤悠志, 他 : 本邦のHIV感染者における慢性腎臓病の有病率2施設での調査結果. 感染症学雑誌 87 : 14-21, 2013
3) Ekrikpo UE, Kengne AP, Bello AK, et al : Chronic kidney disease in the global adult HIV-infected population : a systematic review and meta-analysis. PLoS One 13 : e0195443, 2018
4) 原正樹, 柳澤如樹, 能木場宏彦, 他 : 慢性血液透析に導入されたHIV陽性患者9症例の臨床経過と生命予後. 透析会誌 47 : 435-440, 2014
5) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 東京, 2018
6) 秋葉隆, 日ノ下文彦 : HIV感染患者における透析医療の推進に関する調査. 透析会誌 46 : 111-118, 2013
7) 日ノ下文彦, 秋葉隆 : HIV感染患者における透析医療の推進に関する第2次調査. 透析会誌 51 : 23-31, 2019
8) Finelli L, Miller JT, Tokars JI, et al : National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18 : 52-61, 2005
9) Ippolito G, Puro V, De Carli G : The risk of occupational human immunodeficiency virus infection in health care workers. The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med 153 : 1451-1458, 1993
10) Bell DM : Occupational risk of human immunodeficiency virus infection in healthcare workers : an overview. Am J Med 102 (Suppl 5B) : 9-15, 1997
11) HIV感染患者透析医療ガイド改訂版策定グループHIV感染患者透析医療ガイド改訂版2019. 厚生労働省エイズ対策政策研究事業HIV感染症の医療体制の整備に関する研究班, 東京, 2019
12) 日本透析医会 : 透析医療における標準的な透析操作と感染予防に関するガイドライン (四訂版), 三秀社, 東京, 2015
13) 日ノ下文彦 : 1. HIVの個別予防策. 2. 肝炎ウイルスを除く感染症の個別予防策と治療. 第II章 感染予防各論. 秋葉隆 (編) : 透析医療における感染症予防・治療マニュアル, pp110-119, 日本メディカルセンター, 東京, 2005
14) 日ノ下文彦, 照屋勝治, 勝木俊 : HIV感染透析患者受入れに関する疑問にお答えします (http://www.haart-support.jp/pdf/h28_touseki.pdf)
P.422 掲載の参考文献
1) World Health Organization : Leptospirosis Burden Epidemiology Reference Group (LERG). https://www.who.int/zoonoses/diseases/lerg/en/ (Accessed on April 15, 2019)
2) 小泉信夫, 渡辺治雄 : レプトスピラ症の最新の知見. モダンメディア 52 : 299-305, 2006
3) Haake DA, Levett PN : Leptospirosis in humans. Curr Top Microbiol Immunol 387 : 65-97, 2015
4) IASR Vol. 39, pp202-203, 2018年11月号
5) Bennett JE, Dolin R, Blaser MJ : Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edn, Saunders, 2014
6) 国立感染症研究所. レプトスピラ症の検査依頼について. http://www.niid.go.jp/niid/ja/leptospirosis-m/522-leptospirosis-exam/707-lepto-exam.html (Accessed on April 15, 2019).
P.427 掲載の参考文献
1) Abdulkader RC, Silva MV : The kidney in leptospirosis. Pediatr Nephrol 23 : 2111-2120, 2008
2) Visith S, Kearkiat P : Nephropathy in leptospirosis. J Postgrad Med 51 : 184-188, 2005
3) 斎藤光正 : レプトスピラ感染症. 小児内科増刊号 46 : 1087-1093, 2014
4) 小泉信夫, 岡野祥, 喜屋武向子, 他 : 沖縄県におけるレプトスピラ症患者の発生状況. IASR 37 : 105-106, 2016
5) Covic A, Goldsmith DJ, Gusbeth-Tatomir P, et al : A retrospective 5-year study in Moldova of acute renal failure due to leptospirosis : 58 cases and a review of the literature. Nephrol Dial Transplant 18 : 1128-1134, 2003
P.431 掲載の参考文献
1) World Health Organization : World Malaria Report 2017. WHO Global Malaria Programme, 2018
2) World Health Organization : Guidelines for the treatment of malaria, 2015
3) Silva GBD Junior, Pinto JR, Barros EJG, et al : Kidney involvement in malaria : an update. Rev Inst Med Trop Sao Paulo 59 : e53, 2017
4) Das BS : Renal failure in malaria. J Vector Borne Dis 45 : 83-97, 2008
5) 国立国際医療研究センター国際感染症センター : マラリア診断・治療・予防の手引き (https://www.dccncgm.info/resource/)
P.436 掲載の参考文献
1) Ramos E, Drachenberg CB, Wali R, et al : The decade of polyomavirus BK-associated nephropathy : state of affairs. Transplantation 87 : 621-630, 2009
2) Hirsch HH, Brennan DC, Drachenberg CB, et al : Polyomavirus-associated nephropathy in renal transplantation : interdisciplinary analyses and recommendations. Transplantation 79 : 1277-1286, 2005
3) Bischof N, Hirsch HH, Wehmeier C, et al : Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation : long-term outcomes. Nephrol Dial Transplant, 2018 Nov 23 [Epub ahead of print]
4) 日本臨床腎移植学会ガイドライン作成委員会 : 腎移植後サイトメガロウイルス感染症の診療ガイドライン 2011, 日本医学館, 東京, 2011
5) Kidney Disease : Improving Global Outcomes (KDIGO) Transplant Work Group : KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 (Suppl 3) : S1-S155, 2009
6) Huprikar S, Danziger-Isakov L, Ahn J, et al : Solid organ transplantation from hepatitis B virus-positive donors : consensus guidelines for recipient management. Am J Transplant 15 : 1162-1172, 2015
7) Unagami K, Ishida H, Okumi M, et al : Assessment of 4 cases of kidney transplantation from hepatitis C virus antibody-positive and RNA-negative donors to antibody-negative recipients. Transplant Direct 26 : e102, 2016
8) 日本臨床腎移植学会ガイドライン委員会 : HCV genotypeに応じたHCV抗体陽性ドナー及びHCV抗体陽性レシピエントの取り扱い (https://www.jscrt.jp)
9) 日本臨床腎移植学会ホームページ : 厚生労働省からのお知らせ 心臓及び腎臓移植後患者へのE型肝炎ウイルスの感染例について (周知) (https://www.jscrt.jp)
10) 日本移植学会成人臓器移植予防接種ガイドライン策定委員会 : 成人臓器移植予防接種ガイドライン 2018年度版, メディカルレビュー社, 東京, 2018
P.440 掲載の参考文献
1) Aboumarzouk OM, Hughes O, Narahari K, et al : Emphysematous pyelonephritis : time for a management plan with an evidence-based approach. Arab J Urol 12 : 106-115, 2014
2) Huang JJ, Tseng CC : Emphysematous pyelonephritis : clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 27 : 797-805, 2000
3) Shaeffer AJ, et al : Renal abscess. Wein AJ, Kavoussi
4) 和田耕一郎, 小林泰之 : 腎膿瘍・腎周囲膿瘍. 腎と透析 81 : 564-568, 2016
LR, Partin AW, et al (eds) : Campbell-Walsh Urology, 11th Ed, pp280-283, Elsevier, Netherlands, 2016

第7章 遺伝性疾患

P.445 掲載の参考文献
1) Kashtan CE, Ding J, Garosi G, et al : Alport syndrome : a unified classification of genetic disorders of collagen IV α345 : a position paper of the Alport Syndrome Classification Working Group. Kidney Int 93 : 1045-1051, 2018
2) 日本小児腎臓病学会 (編) : アルポート症候群診療ガイドライン 2017, pp1-85, 診断と治療社, 東京, 2017
3) Nakanishi K, Yoshikawa N, Iijima K, et al : Immunohistochemical study of α1-5 chains of type IV collagen in hereditary nephritis. Kidney Int 46 : 1413-1421, 1994
4) Hashimura Y, Nozu K, Kaito H, et al : Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV α5 chain. Kidney Int 85 : 1208-1213, 2014
P.448 掲載の参考文献
1) Bongers EM, Huysmans FT, Levtchenko E, et al : Genotype-phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy. Eur J Hum Genet 13 : 935-946, 2005
2) Harita Y, Kitanaka S, Isojima T, et al : Spectrum of LMX1B mutations : from nail-patella syndrome to isolated nephropathy. Pediatr Nephrol 32 : 1845-1850, 2017
3) Dreyer SD, Zhou G, Baldini A, et al : Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 19 : 47-50, 1998
4) Ghoumid J, Petit F, Holder-Espinasse M, et al : Nail-patella syndrome : clinical and molecular data in 55 families raising the hypothesis of a genetic heterogeneity. Eur J Hum Genet 24 : 44-50, 2016
5) Lemley KV : Kidney disease in nail-patella syndrome. Pediatr Nephrol 24 : 2345-2354, 2009
P.453 掲載の参考文献
1) Halbritter J, Porath JD, Diaz KA, et al ; GPN Study Group : Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy. Hum Genet 132 : 865-884, 2013
3) Sugimoto K, Miyazawa T, Enya T, et al : Clinical and genetic characteristics of Japanese nephronophthisis patients. Clin Exp Nephrol 20 : 637-649, 2016
4) 竹村司 : Nephrocystin. 腎と透析 63 : 547-549, 2007
5) Braun DA, Schueler M, Halbritter J, et al : Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity. Kidney Int 89 : 468-475, 2016
P.458 掲載の参考文献
1) Leffler J, Bengtsson AA, Blom AM : The complement system in systemic lupus erythematosus : an update. Ann Rheum Dis 73 : 1601-1606, 2014
2) Jonsson G, Sjoholm AG, Truedsson L, et al : Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology 46 : 1133-1139, 2007
3) Kitamura H, Nagaki K, Inai S : Further studies on C9 deficiency. J Clin Lab Immunol 6 : 7-11, 1981
4) Kato H, Nangaku M, Hataya H, et al : Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20 : 536-543, 2016
5) Matsumoto M : Consensus report on the diagnosis and management of thrombotic thrombocytopenic purpura 2017. Rinsho Ketsueki 58 : 271-281, 2017
6) Noris M, Donadelli R, Remuzzi G : Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol, 2018 Jun 9 [Epub ahead of print]
7) Goicoechea de Jorge E, Caesar JJ, Malik TH, et al : Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci USA 110 : 4685-4690, 2013
8) De Vriese AS, Sethi S, Van Praet J, et al : Kidney disease caused by dysregulation of the complement alternative pathway : an etiologic approach. J Am Soc Nephrol 26 : 2917-2929, 2015
9) Tortajada A, Gutierrez E, Goicoechea de Jorge E, et al : Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int 92 : 953-963, 2017
10) Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, et al : Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int 92 : 942-952, 2017
11) Jullien P, Laurent B, Claisse G, et al : Deletion variants of CFHR1 and CFHR3 associate with mesangial immune deposits but not with progression of IgA nephropathy. J Am Soc Nephrol 29 : 661-669, 2018
12) Zhu L, Guo WY, Shi SF, et al : Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy. Kidney Int 94 : 150-158, 2018
13) Loirat C, Fakhouri F, Ariceta G, et al : An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31 : 15-39, 2016
14) Legendre CM, Licht C, Muus P, et al : Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 : 2169-2181, 2013
15) Licht C, Greenbaum LA, Muus P, et al : Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 : 1061-1073, 2015
16) Kato H, Miyakawa Y, Hidaka Y, et al : Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan : interim analysis of post-marketing surveillance. Clin Exp Nephrol 23 : 65-75, 2019
17) Ito S, Hidaka Y, Inoue N, et al : Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan : interim analysis of post-marketing surveillance. Clin Exp Nephrol 23 : 112-121, 2019
18) Fujisawa M, Kato H, Yoshida Y, et al : Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 22 : 1088-1099, 2018
19) Riedl M, Thorner P, Licht C : C3 Glomerulopathy. Pediatr Nephrol 32 : 43-57, 2017
20) Vivarelli M, Emma F : Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40 : 472-477, 2014
P.462 掲載の参考文献
2) Nauli SM, Alenghat FJ, Luo Y, et al : Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 33 : 129-137, 2003
4) Irazabal MV, Rangel LJ, Bergstralh EJ, et al : Imaging classification of autosomal dominant polycystic kidney disease : a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26 : 160-172, 2015
P.466 掲載の参考文献
1) Guay-Woodford LM, Bissler JJ, Braun MC, et al : Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease : report of an international conference. J Pediatr 165 : 611-617, 2014
2) Kolb RJ, Nauli SM : Ciliary dysfunction in polycystic kidney disease : an emerging model with polarizing potential. Front Biosci 13 : 4451-4466, 2008
3) Bergmann C, Senderek J, Windelen E, et al : Clinical consequences of PKHD1 mutations in 164 patients with autosomal recessive polycystic kidney disease (ARPKD). Kidney Int 67 : 829-848, 2005
4) Lu H, Galeano MCR, Ott E, et al : Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet 49 : 1025-1034, 2017
5) Guay-Woodford LM, Desmond RA : Autosomal recessive polycystic kidney disease : the clinical experience in North America. Pediatrics 111 : 1072-1180, 2003
6) Gunay-Aygun M, Font-Montgomery E, Lukose L, et al : Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 5 : 972-984, 2010
7) Dell KM, Sweeney WE, Avner ED : Polycystic kidney disease. In : Avner ED, Harmon WE, Niaudet P, et al (eds) : Pediatric Nephrology, 6th Edn, Springer, pp849-887, 2009
8) 三浦健一郎, 金井孝裕, 久野正貴, 他 : 食道静脈瘤を呈した常染色体劣性多発性嚢胞腎の1女児例に対する先行的生体腎移植. 日児誌 111 : 1181-1185, 2007
9) 水谷誠, 近本裕子, 上田博章, 他 : 常染色体劣性多発性嚢胞腎の臨床像-単一施設における小児10症例の検討-. 日児腎誌 23 : 123-127, 2010
10) Khan K, Schwarzenberg SJ, Sharp HL, et al : Morbidity from congenital hepatic fibrosis after renal transplantation for autosomal recessive polycystic kidney disease. Am J Transplant 2 : 360-365, 2002
11) Telega G, Cronin D, Avner ED : New approaches to the autosomal recessive polycystic kidney disease patient with dual kidney-liver complications. Pediatr Transplant 17 : 328-335, 2013
12) 苗代有鈴, 三浦健一郎, 石塚喜世伸, 他 : 二期的生体肝腎移植を施行した常染色体劣性多発性嚢胞腎の2例. 日児誌 121 : 1846-1851, 2017

第8章 電解質異常

P.470 掲載の参考文献
2) Minisola S, Pepe J, Piemonte S, et al : The diagnosis and management of hypercalcemia. BMJ 350 : h2723, 2015
3) Donovan PJ, Sundac L, Pretorius CJ, et al : Calcitriol-mediated hypercalcemia : causes and course in 101 patients. J Clin Endocrinol Metab 98 : 4023-4029, 2013
P.473 掲載の参考文献
1) 本田浩一 : 生活習慣病に必要な水と塩分調節-Ca, P, Mgの調節. 成人病と生活習慣病 48 : 270-271, 2018
2) 横山啓太郎 : 高カルシウム血症, 低カルシウム血症. 腎と透析 80 増 (腎と透析診療指針 2016) : 68-75, 2016
P.480 掲載の参考文献
1) Gennari FJ : Hypokalemia. N Engl J Med 339 : 451-458, 1988
2) 深川雅史 (監修), 柴垣有吾 : より理解を深める! 体液電解質異常と輸液改訂3版, pp108-115, 中外医学社, 東京, 2015
3) Mount DB : Transport of sodium, chloride, and potassium. In : Skorecki K, Chertow GM, Marsden PA, et al (eds) : Brenner & Rector's The Kidney, 10th Ed, pp174-183, Elsevier, Philadelphia, 2016
4) Mount DB : Disorders of potassium balance. In : Skorecki K, Chertow GM, Marsden PA, et al (eds) : Brenner & Rector's The Kidney, 10th Ed, pp.558-585, Elsevier, Philadelphia, 2016
5) Yalamanchili HB, Calp-Inal S, Zhou XJ, et al : Hypokalemic nephropathy. Kidney Int Rep 3 : 1482-1488, 2018

第9章 その他

P.483 掲載の参考文献
1) Pruitt BA and Mason AD : Total Burn Care (Herndon DN ed), pp5-15, WB Saunders, London, 1996
2) Evans EL, Purnell OJ, Robinett PW, et al : Fluid and electrolyte requirements in severe burns. Ann Surg 135 : 804-817, 1952
3) Arturson G : Microvascular permeability to macromolecules in thermal injury. Acta Physiol Scand 463 (Suppl) : 111-122, 1979
4) 齋藤大蔵, 岡田芳明 : 熱傷急性期における輸液療法. 医学のあゆみ 183 : 683-686, 1997
5) 日本熱傷学会 (編) : 熱傷診療ガイドライン : 初期輸液, pp29-41, 春恒社, 東京, 2015
6) Baxter CR, Shires T : Physiological response to crystalloid resuscitation of severe burns. Ann NY Acad Sci 150 : 874-894, 1968
7) Pruitt BA Jr : Protection from excessive resuscitation : "pushing the pendulum back". J Trauma 49 : 567-568, 2000
8) Advanced Burn Life Support Course Provider Manual 2011, pp41-51, American Burn Association, Chicago, 2011
P.487 掲載の参考文献
1) Mustonen KM, Vuola J : Acute renal failure in intensive care burn patients (ARF in burn patients). J Burn Care Res 29 : 227-237, 2008
2) Saffle JI : The phenomenon of "fluid creep" in acute burn resuscitation. J Burn Care Res 28 : 382-395, 2007
3) ISBI Practice Guidelines Committee : ISBI practice guidelines for burn care. Burns 42 : 953-1021, 2016
4) 日本熱傷学会 : 熱傷診療ガイドライン 第2版, 2009 (http://www.jsbi-burn.org/members/guideline/pdf/guideline2.pdf), Accessed Jan. 10, 2019
5) ACI Statewide Burn Injury Service. Clinical practice guidelines : burn patient management. 2014 (https://www.aci.health.nsw.gov.au/__data/assets/pdf_file/0009/250020/Burn_Patient_Management_-_Clinical_Practice_Guidelines.pdf), Accessed Jan. 10, 2019
6) European Burns Association. European practice guidelines for burn care. 2015 (http://euroburn.org/wp-content/uploads/2016/04/EBA-Guidelines-Version-3-2015.pdf), Accessed Jan. 10, 2019
7) Pham TN, Cancio LC, Gibran NS, et al : American Burn Association practice guidelines burn shock resuscitation. J Burn Care Res 29 : 257-266, 2008
8) Huang PP, Stucky FS, Dimick AR, et al : Hypertonic sodium resuscitation is associated with renal failure and death. Ann Surg 221 : 543-554, 1995
9) Baxter CR : Fluid volume and electrolyte changes of the early postburn period. Clin Plast Surg 1 : 693-703, 1974
10) Pruitt BA Jr : Fluid and electrolyte replacement in the burned patient. Surg Clin North Am 58 : 1291-1312, 1978
11) Chung KK, Blackbourne LH, Wolf SE, et al : Evolution of burn resuscitation in operation Iraqi freedom. J Burn Care Res 27 : 606-611, 2006
12) Paratz JD, Stockton K, Paratz ED, et al : Burn resuscitation hourly urine output versus alternative endpoints : a systematic review. Shock 42 : 295-306, 2014
13) Kuwa T, Jordan BS, Cancio LC : Use of power Doppler ultrasound to monitor renal perfusion during burn shock. Burns 32 : 706-713, 2006
14) 太田宗夫, 金子正光, 黒川顕, 他 : 重症熱傷に伴う溶血と急性期腎機能低下の防止に対するハプトグロビンの有用性の検討-封筒法による多施設比較試験. 救急医学 16 : 1813-1819, 1992
15) 大須賀章倫, 黒木雄一, 宮尾大樹, 他 : 熱傷蘇生輸液. 日本救急医学会雑誌 26 : 647-656, 2015
P.490 掲載の参考文献
1) 花房規男 : 横紋筋融解症. 腎と透析 76 : 617-622, 2014
2) 村井ユリ子, 他 : 横紋筋融解症に関する副作用情報の評価と活用 (解説). 医薬ジャーナル 38 : 1773-1782, 2002
3) Zimmerman JL, Shen MC : Rhabdomyolysis. Chest 144 : 1058-1065, 2013
5) Petejova N, Martinek A : Acute kidney injury due to rhabdomyolysis and renal replacement therapy : a critical review. Crit Care 18 : 224, 2014
P.493 掲載の参考文献
1) Collins AJ : Kidney dialysis treatment for victims of the Armenian earthquake. N Engl J Med 320 : 1291-1292, 1989
3) McMahon GM, Zeng X, Waikar SS : A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Intern Med 173 : 1821-1828, 2013
4) Melli G, Chaudhry V, Cornblath DR : Rhabdomyolysis : an evaluation of 475 hospitalized patients. Medicine (Baltimore) 84 : 377-385, 2005
5) Okubo K, Kurosawa M, Kamiya M, et al : Macrophage extracellular trap formation promoted by platelet activation is a key mediator of rhabdomyolysis-induced acute kidney injury. Nat Med 24 : 232-238, 2018
6) Neyra JA, Rocha NA, Bhargava R, et al : Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone : a case report. BMC Nephrol 16 : 118, 2015
7) Brown CV, Rhee P, Chan L : Preventing renal failure in patients with rhabdomyolysis : do bicarbonate and mannitol make a difference? J Trauma 56 : 1191-1196, 2004
8) 日本腎臓学会 : AKI (急性腎障害) 診療ガイドライン 2016. 日腎会誌 59 : 419-533, 2017
9) Bolisetty S, Zarjou A, Agarwal A : Heme oxygenase 1 as a therapeutic target in acute kidney injury. Am J Kidney Dis 69 : 531-545, 2017
P.496 掲載の参考文献
1) 日本救急医学会 (監) : 熱中症改訂 第2版-日本を襲う熱波の恐怖, へるす出版, 東京, 2017
2) 日本救急医学会 (監) : 救急診療指針改訂第5版, pp539-541, へるす出版, 東京, 2018
3) 日本救急医学会熱中症に関する委員会 : 熱中症診療ガイドライン 2015, 2015
4) 中村俊介, 三宅康史, 土肥謙二, 他 : 熱中症による中枢神経系後遺症-Heatstroke STUDY 2006, Heatstroke STUDY 2008の結果分析-. 日救急医会誌 22 : 312-318, 2011
5) Davis BC, Tillman H, Chung RT, et al : Heat stroke leading to acute liver injury & failure : a case series from the Acute Liver Failure Study Group. Liver Int 37 : 509-513, 2017
P.502 掲載の参考文献
1) 石井友理, 他 : 熱中症・脱水症への対応法. 耳喉頭頸 85 (増刊) : 54-59, 2013
2) 三宅康史 : 熱中症の電解質異常と輸液療法. medicina 55 : 1070-1076, 2018
3) 日本救急医学会 : 熱中症診療ガイドライン 2015, 2015
4) 藤元昭一 : 熱中症での輸液療法. medicina 40 : 1898-1901, 2003
5) Satirapoj B, Kongthaworn S, Choovichian P, et al : Electrolyte disturbances and risk factors of acute kidney injury patients receiving dialysis in exertional heat stroke. BMC Nephrol 17 : 55, 2016
P.507 掲載の参考文献
1) Seki H : Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia. Acta Obstet Gynecol Scand 93 : 959-964, 2014
2) Levine RJ, Maynard SE, Qian C, et al : Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 : 672-683, 2004
3) Cunningham FG, Leveno KJ, Bloom SL, et al (eds) : Williams OBSTETRICS 24th Edn, Chapter 4 Maternal physiology, pp46-77, McGraw-Hill Education, 2014
4) 日本妊娠高血圧学会 (編) : 妊娠高血圧症候群の診療指針 2015, VI 腎疾患合併妊娠, pp120-135, メジカルビュー社, 東京, 2015
5) Seki H, Takeda S, Kinoshita K : Long-term treatment with nicardipine for severe pre-eclampsia. Int J Gynaecol Obstet 76 : 135-141, 2002
6) Matsumura H, Takagi K, Seki H, et al : Placental transfer of intravenous nicardipine and disposition into breast milk during the control of hypertension in women with pre-eclampsia. Hypertens Pregnancy 33 : 93-101, 2014
P.513 掲載の参考文献
1) Imai Y : Clinical significance of home blood pressure and its possible practical application. Clin Exp Nephrol 18 : 24-40, 2014
2) Metoki H, Ohkubo T, Obara T, et al : Daily serial hemodynamic data during pregnancy and seasonal variation : the BOSHI study. Clin Exp Hypertens 34 : 290-296, 2012
3) Tucker KL, Bankhead C, Hodgkinson J, et al : How do home and clinic blood pressure readings compare in pregnancy? Hypertension 72 : 686-694, 2018
4) Chapman AB : The structure-function relationship in preeclampsia. Kidney Int 54 : 1394-1395, 1998
5) Conrad KP, Benyo DF : Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 37 : 240-249, 1997
6) Karumanchi SA, Lindheimer MD : Advances in the understanding of eclampsia. Curr Hypertens Rep 10 : 305-312, 2008